Trial Outcomes & Findings for A Study to Evaluate the Safety and Tolerability of ABBV-951 in Subjects With Parkinson's Disease (PD) (NCT NCT03781167)

NCT ID: NCT03781167

Last Updated: 2023-10-23

Results Overview

An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study drug. A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above. Treatment-emergent adverse events/treatment-emergent serious adverse events (TEAEs/TESAEs) are defined as any event that began or worsened in severity on or after the first dose of study drug.

• Recruitment status: COMPLETED
• Study phase: PHASE3
• Target enrollment: 244 participants
• Primary outcome timeframe: From first dose of study drug until 30 days following last dose of study drug (up to 480 days)
• Results posted on: 2023-10-23

Participant Flow

All enrolled participants

Participant milestones

Measure	ABBV-951 Low Dose Subgroup After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was \< 2530 mg of Foslevodopa/day were analyzed as the Low Dose Subgroup.	ABBV-951 High Dose Subgroup After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was ≥ 2530 mg of Foslevodopa/day were analyzed as the High Dose Subgroup.
Overall Study STARTED	131	113
Overall Study COMPLETED	84	65
Overall Study NOT COMPLETED	47	48

Reasons for withdrawal

Measure	ABBV-951 Low Dose Subgroup After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was \< 2530 mg of Foslevodopa/day were analyzed as the Low Dose Subgroup.	ABBV-951 High Dose Subgroup After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was ≥ 2530 mg of Foslevodopa/day were analyzed as the High Dose Subgroup.
Overall Study Adverse Event	23	25
Overall Study Withdrew consent	16	12
Overall Study Lost to Follow-up	0	1
Overall Study Lack of Efficacy	4	5
Overall Study Difficulty with drug delivery system	2	3
Overall Study Other, not specified	2	2

Baseline Characteristics

A Study to Evaluate the Safety and Tolerability of ABBV-951 in Subjects With Parkinson's Disease (PD)

Baseline characteristics by cohort

Measure	ABBV-951 Low Dose Subgroup n=131 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was \< 2530 mg of Foslevodopa/day were analyzed as the Low Dose Subgroup.	ABBV-951 High Dose Subgroup n=113 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was ≥ 2530 mg of Foslevodopa/day were analyzed as the High Dose Subgroup.	Total n=244 Participants Total of all reporting groups
Age, Continuous	63.5 years STANDARD_DEVIATION 8.87 • n=5 Participants	64.4 years STANDARD_DEVIATION 9.54 • n=7 Participants	63.9 years STANDARD_DEVIATION 9.18 • n=5 Participants
Sex: Female, Male Female	66 Participants n=5 Participants	32 Participants n=7 Participants	98 Participants n=5 Participants
Sex: Female, Male Male	65 Participants n=5 Participants	81 Participants n=7 Participants	146 Participants n=5 Participants
Ethnicity (NIH/OMB) Hispanic or Latino	8 Participants n=5 Participants	12 Participants n=7 Participants	20 Participants n=5 Participants
Ethnicity (NIH/OMB) Not Hispanic or Latino	123 Participants n=5 Participants	101 Participants n=7 Participants	224 Participants n=5 Participants
Ethnicity (NIH/OMB) Unknown or Not Reported	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants
Race (NIH/OMB) American Indian or Alaska Native	1 Participants n=5 Participants	0 Participants n=7 Participants	1 Participants n=5 Participants
Race (NIH/OMB) Asian	27 Participants n=5 Participants	7 Participants n=7 Participants	34 Participants n=5 Participants
Race (NIH/OMB) Native Hawaiian or Other Pacific Islander	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants
Race (NIH/OMB) Black or African American	0 Participants n=5 Participants	1 Participants n=7 Participants	1 Participants n=5 Participants
Race (NIH/OMB) White	102 Participants n=5 Participants	105 Participants n=7 Participants	207 Participants n=5 Participants
Race (NIH/OMB) More than one race	1 Participants n=5 Participants	0 Participants n=7 Participants	1 Participants n=5 Participants
Race (NIH/OMB) Unknown or Not Reported	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants

PRIMARY outcome

Timeframe: From first dose of study drug until 30 days following last dose of study drug (up to 480 days)

Population: Safety Analysis Set: all participants who received any ABBV-951 infusion

An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study drug. A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above. Treatment-emergent adverse events/treatment-emergent serious adverse events (TEAEs/TESAEs) are defined as any event that began or worsened in severity on or after the first dose of study drug.

Outcome measures

Measure	ABBV-951 Low Dose Subgroup n=131 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was \< 2530 mg of Foslevodopa/day were analyzed as the Low Dose Subgroup.	ABBV-951 High Dose Subgroup n=113 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was ≥ 2530 mg of Foslevodopa/day were analyzed as the High Dose Subgroup.	ABBV-951 All Participants n=244 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period.
Number of Participants With Adverse Events Any TEAE	121 Participants	109 Participants	230 Participants
Number of Participants With Adverse Events TESAE	32 Participants	31 Participants	63 Participants

PRIMARY outcome

Timeframe: From first dose of study drug until 30 days following last dose of study drug (up to 480 days)

Population: Safety Analysis Set: all participants who received any ABBV-951 infusion

Treatment emergent adverse events of special interest are defined as any adverse event of infusion site infections, infusion site reactions, hallucinations/psychosis, falls and associated injuries, polyneuropathy (peripheral neuropathy), weight loss, or somnolence from the first dose of study drug until 30 days following last dose of study drug.

Outcome measures

Measure	ABBV-951 Low Dose Subgroup n=131 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was \< 2530 mg of Foslevodopa/day were analyzed as the Low Dose Subgroup.	ABBV-951 High Dose Subgroup n=113 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was ≥ 2530 mg of Foslevodopa/day were analyzed as the High Dose Subgroup.	ABBV-951 All Participants n=244 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period.
Number of Participants With Adverse Events of Special Interest Infusion site infections	42 Participants	44 Participants	86 Participants
Number of Participants With Adverse Events of Special Interest Infusion site reactions	103 Participants	97 Participants	200 Participants
Number of Participants With Adverse Events of Special Interest Hallucinations/psychosis	32 Participants	29 Participants	61 Participants
Number of Participants With Adverse Events of Special Interest Falls and associated injuries	37 Participants	37 Participants	74 Participants
Number of Participants With Adverse Events of Special Interest Polyneuropathy (peripheral neuropathy)	14 Participants	13 Participants	27 Participants
Number of Participants With Adverse Events of Special Interest Weight loss	12 Participants	15 Participants	27 Participants
Number of Participants With Adverse Events of Special Interest Somnolence	9 Participants	3 Participants	12 Participants

PRIMARY outcome

Timeframe: Day 1, Day 2, Week 1, Week 2, Week 3, Week 4, Week 6, Week 13, Week 26, Week 39, and Week 52

Population: Safety Analysis Set: all participants who received any ABBV-951 infusion

Skin tolerability was assessed using the Infusion Site Evaluation Scale, a 2-part numeric (0-7) and letter (A-G) grade scale, where a notable skin reaction is defined as a reaction with a numeric grade of 6 or 7 or a letter grade of D, E, F, or G. Any observation of infusion site reaction with irritation criteria > 2 or > C was recorded as an adverse event (AE).

Outcome measures

Measure	ABBV-951 Low Dose Subgroup n=131 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was \< 2530 mg of Foslevodopa/day were analyzed as the Low Dose Subgroup.	ABBV-951 High Dose Subgroup n=113 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was ≥ 2530 mg of Foslevodopa/day were analyzed as the High Dose Subgroup.	ABBV-951 All Participants n=244 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period.
Number of Participants With Numeric Grade Equal to or Higher Than 5 and With Letter Grade Equal to or Higher Than D on the Infusion Site Evaluation Scale	10 Participants	15 Participants	25 Participants

PRIMARY outcome

Timeframe: Baseline, Weeks 6, 26, 39, and 52

Population: Safety Analysis Set: all participants who received any ABBV-951 infusion with available data

Samples for clinical laboratory tests were collected at study visits, and a certified central laboratory was used to process the samples and provide results.

Outcome measures

Measure	ABBV-951 Low Dose Subgroup n=128 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was \< 2530 mg of Foslevodopa/day were analyzed as the Low Dose Subgroup.	ABBV-951 High Dose Subgroup n=113 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was ≥ 2530 mg of Foslevodopa/day were analyzed as the High Dose Subgroup.	ABBV-951 All Participants n=241 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period.
Hematocrit (Hematology): Change From Baseline to End of Study Week 6	-0.02 proportion of red blood cells in blood Standard Deviation 0.031	-0.02 proportion of red blood cells in blood Standard Deviation 0.029	-0.02 proportion of red blood cells in blood Standard Deviation 0.030
Hematocrit (Hematology): Change From Baseline to End of Study Week 39	-0.02 proportion of red blood cells in blood Standard Deviation 0.028	-0.02 proportion of red blood cells in blood Standard Deviation 0.029	-0.02 proportion of red blood cells in blood Standard Deviation 0.028
Hematocrit (Hematology): Change From Baseline to End of Study Week 52	-0.02 proportion of red blood cells in blood Standard Deviation 0.029	-0.02 proportion of red blood cells in blood Standard Deviation 0.028	-0.02 proportion of red blood cells in blood Standard Deviation 0.029
Hematocrit (Hematology): Change From Baseline to End of Study Week 26	-0.01 proportion of red blood cells in blood Standard Deviation 0.030	-0.02 proportion of red blood cells in blood Standard Deviation 0.026	-0.02 proportion of red blood cells in blood Standard Deviation 0.028

PRIMARY outcome

Timeframe: Baseline, Weeks 6, 26, 39, and 52

Population: Safety Analysis Set: all participants who received any ABBV-951 infusion with available data

Samples for clinical laboratory tests were collected at study visits, and a certified central laboratory was used to process the samples and provide results.

Outcome measures

Measure	ABBV-951 Low Dose Subgroup n=130 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was \< 2530 mg of Foslevodopa/day were analyzed as the Low Dose Subgroup.	ABBV-951 High Dose Subgroup n=113 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was ≥ 2530 mg of Foslevodopa/day were analyzed as the High Dose Subgroup.	ABBV-951 All Participants n=243 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period.
Hemoglobin (Hematology): Change From Baseline to End of Study Week 6	-5.00 g/L Standard Deviation 8.308	-6.82 g/L Standard Deviation 9.222	-5.89 g/L Standard Deviation 8.789
Hemoglobin (Hematology): Change From Baseline to End of Study Week 26	-5.42 g/L Standard Deviation 9.296	-4.48 g/L Standard Deviation 7.502	-4.98 g/L Standard Deviation 8.482
Hemoglobin (Hematology): Change From Baseline to End of Study Week 39	-5.74 g/L Standard Deviation 8.430	-6.58 g/L Standard Deviation 8.601	-6.11 g/L Standard Deviation 8.480
Hemoglobin (Hematology): Change From Baseline to End of Study Week 52	-7.96 g/L Standard Deviation 8.862	-5.80 g/L Standard Deviation 9.308	-6.99 g/L Standard Deviation 9.091

PRIMARY outcome

Timeframe: Baseline, Weeks 6, 26, 39, and 52

Population: Safety Analysis Set: all participants who received any ABBV-951 infusion with available data

Samples for clinical laboratory tests were collected at study visits, and a certified central laboratory was used to process the samples and provide results.

Outcome measures

Measure	ABBV-951 Low Dose Subgroup n=130 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was \< 2530 mg of Foslevodopa/day were analyzed as the Low Dose Subgroup.	ABBV-951 High Dose Subgroup n=113 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was ≥ 2530 mg of Foslevodopa/day were analyzed as the High Dose Subgroup.	ABBV-951 All Participants n=243 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period.
Red Blood Cell (RBC) Count (Hematology): Change From Baseline to End of Study Week 26	-0.12 cells*10^12/L Standard Deviation 0.295	-0.13 cells*10^12/L Standard Deviation 0.273	-0.13 cells*10^12/L Standard Deviation 0.284
Red Blood Cell (RBC) Count (Hematology): Change From Baseline to End of Study Week 39	-0.14 cells*10^12/L Standard Deviation 0.271	-0.19 cells*10^12/L Standard Deviation 0.290	-0.17 cells*10^12/L Standard Deviation 0.279
Red Blood Cell (RBC) Count (Hematology): Change From Baseline to End of Study Week 52	-0.21 cells*10^12/L Standard Deviation 0.291	-0.16 cells*10^12/L Standard Deviation 0.293	-0.19 cells*10^12/L Standard Deviation 0.292
Red Blood Cell (RBC) Count (Hematology): Change From Baseline to End of Study Week 6	-0.15 cells*10^12/L Standard Deviation 0.261	-0.21 cells*10^12/L Standard Deviation 0.296	-0.18 cells*10^12/L Standard Deviation 0.280

PRIMARY outcome

Timeframe: Baseline, Weeks 6, 26, 39, and 52

Population: Safety Analysis Set: all participants who received any ABBV-951 infusion with available data

Samples for clinical laboratory tests were collected at study visits, and a certified central laboratory was used to process the samples and provide results.

Outcome measures

Measure	ABBV-951 Low Dose Subgroup n=130 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was \< 2530 mg of Foslevodopa/day were analyzed as the Low Dose Subgroup.	ABBV-951 High Dose Subgroup n=113 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was ≥ 2530 mg of Foslevodopa/day were analyzed as the High Dose Subgroup.	ABBV-951 All Participants n=243 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period.
White Blood Cell (WBC) Count (Hematology): Change From Baseline to End of Study Week 6	0.02 cells*10^9/L Standard Deviation 1.705	0.32 cells*10^9/L Standard Deviation 2.120	0.17 cells*10^9/L Standard Deviation 1.919
White Blood Cell (WBC) Count (Hematology): Change From Baseline to End of Study Week 39	0.35 cells*10^9/L Standard Deviation 4.014	0.38 cells*10^9/L Standard Deviation 1.670	0.36 cells*10^9/L Standard Deviation 3.202
White Blood Cell (WBC) Count (Hematology): Change From Baseline to End of Study Week 52	-0.08 cells*10^9/L Standard Deviation 2.027	-0.04 cells*10^9/L Standard Deviation 1.568	-0.06 cells*10^9/L Standard Deviation 1.829
White Blood Cell (WBC) Count (Hematology): Change From Baseline to End of Study Week 26	0.12 cells*10^9/L Standard Deviation 1.892	0.22 cells*10^9/L Standard Deviation 2.990	0.17 cells*10^9/L Standard Deviation 2.460

PRIMARY outcome

Timeframe: Baseline, Weeks 6, 26, 39, and 52

Population: Safety Analysis Set: all participants who received any ABBV-951 infusion with available data

Samples for clinical laboratory tests were collected at study visits, and a certified central laboratory was used to process the samples and provide results.

Outcome measures

Measure	ABBV-951 Low Dose Subgroup n=130 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was \< 2530 mg of Foslevodopa/day were analyzed as the Low Dose Subgroup.	ABBV-951 High Dose Subgroup n=113 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was ≥ 2530 mg of Foslevodopa/day were analyzed as the High Dose Subgroup.	ABBV-951 All Participants n=243 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period.
Neutrophils (Hematology): Change From Baseline to End of Study Week 6	0.01 cells*10^9/L Standard Deviation 1.720	0.33 cells*10^9/L Standard Deviation 2.102	0.17 cells*10^9/L Standard Deviation 1.917
Neutrophils (Hematology): Change From Baseline to End of Study Week 26	-0.03 cells*10^9/L Standard Deviation 1.813	143.08 cells*10^9/L Standard Deviation 1133.988	67.25 cells*10^9/L Standard Deviation 777.558
Neutrophils (Hematology): Change From Baseline to End of Study Week 39	-0.23 cells*10^9/L Standard Deviation 2.380	0.18 cells*10^9/L Standard Deviation 1.635	-0.05 cells*10^9/L Standard Deviation 2.089
Neutrophils (Hematology): Change From Baseline to End of Study Week 52	-0.14 cells*10^9/L Standard Deviation 1.986	-0.04 cells*10^9/L Standard Deviation 1.498	-0.10 cells*10^9/L Standard Deviation 1.778

PRIMARY outcome

Timeframe: Baseline, Weeks 6, 26, 39, and 52

Population: Safety Analysis Set: all participants who received any ABBV-951 infusion with available data

Samples for clinical laboratory tests were collected at study visits, and a certified central laboratory was used to process the samples and provide results.

Outcome measures

Measure	ABBV-951 Low Dose Subgroup n=130 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was \< 2530 mg of Foslevodopa/day were analyzed as the Low Dose Subgroup.	ABBV-951 High Dose Subgroup n=113 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was ≥ 2530 mg of Foslevodopa/day were analyzed as the High Dose Subgroup.	ABBV-951 All Participants n=243 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period.
Lymphocytes (Hematology): Change From Baseline to End of Study Week 6	0.06 cells*10^9/L Standard Deviation 0.305	-0.07 cells*10^9/L Standard Deviation 0.326	0.00 cells*10^9/L Standard Deviation 0.321
Lymphocytes (Hematology): Change From Baseline to End of Study Week 26	0.09 cells*10^9/L Standard Deviation 0.331	13.92 cells*10^9/L Standard Deviation 110.588	6.59 cells*10^9/L Standard Deviation 75.823
Lymphocytes (Hematology): Change From Baseline to End of Study Week 39	0.03 cells*10^9/L Standard Deviation 0.394	0.04 cells*10^9/L Standard Deviation 0.312	0.03 cells*10^9/L Standard Deviation 0.359
Lymphocytes (Hematology): Change From Baseline to End of Study Week 52	0.04 cells*10^9/L Standard Deviation 0.394	-0.05 cells*10^9/L Standard Deviation 0.294	0.00 cells*10^9/L Standard Deviation 0.354

PRIMARY outcome

Timeframe: Baseline, Weeks 6, 26, 39, and 52

Population: Safety Analysis Set: all participants who received any ABBV-951 infusion with available data

Samples for clinical laboratory tests were collected at study visits, and a certified central laboratory was used to process the samples and provide results.

Outcome measures

Measure	ABBV-951 Low Dose Subgroup n=130 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was \< 2530 mg of Foslevodopa/day were analyzed as the Low Dose Subgroup.	ABBV-951 High Dose Subgroup n=113 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was ≥ 2530 mg of Foslevodopa/day were analyzed as the High Dose Subgroup.	ABBV-951 All Participants n=243 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period.
Monocytes (Hematology): Change From Baseline to End of Study Week 52	0.00 cells*10^9/L Standard Deviation 0.109	0.01 cells*10^9/L Standard Deviation 0.132	0.00 cells*10^9/L Standard Deviation 0.119
Monocytes (Hematology): Change From Baseline to End of Study Week 6	0.01 cells*10^9/L Standard Deviation 0.127	0.01 cells*10^9/L Standard Deviation 0.123	0.01 cells*10^9/L Standard Deviation 0.125
Monocytes (Hematology): Change From Baseline to End of Study Week 26	0.02 cells*10^9/L Standard Deviation 0.095	17.43 cells*10^9/L Standard Deviation 138.498	8.21 cells*10^9/L Standard Deviation 94.963
Monocytes (Hematology): Change From Baseline to End of Study Week 39	0.02 cells*10^9/L Standard Deviation 0.120	0.03 cells*10^9/L Standard Deviation 0.122	0.02 cells*10^9/L Standard Deviation 0.120

PRIMARY outcome

Timeframe: Baseline, Weeks 6, 26, 39, and 52

Population: Safety Analysis Set: all participants who received any ABBV-951 infusion with available data

Samples for clinical laboratory tests were collected at study visits, and a certified central laboratory was used to process the samples and provide results.

Outcome measures

Measure	ABBV-951 Low Dose Subgroup n=130 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was \< 2530 mg of Foslevodopa/day were analyzed as the Low Dose Subgroup.	ABBV-951 High Dose Subgroup n=112 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was ≥ 2530 mg of Foslevodopa/day were analyzed as the High Dose Subgroup.	ABBV-951 All Participants n=242 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period.
Absolute Platelet Count (Hematology): Change From Baseline to End of Study Week 6	4.59 cells*10^9/L Standard Deviation 36.489	0.39 cells*10^9/L Standard Deviation 40.844	2.54 cells*10^9/L Standard Deviation 38.635
Absolute Platelet Count (Hematology): Change From Baseline to End of Study Week 52	-3.41 cells*10^9/L Standard Deviation 41.120	-10.63 cells*10^9/L Standard Deviation 44.537	-6.58 cells*10^9/L Standard Deviation 42.628
Absolute Platelet Count (Hematology): Change From Baseline to End of Study Week 26	-1.68 cells*10^9/L Standard Deviation 43.279	-10.39 cells*10^9/L Standard Deviation 43.757	-5.74 cells*10^9/L Standard Deviation 43.556
Absolute Platelet Count (Hematology): Change From Baseline to End of Study Week 39	-3.90 cells*10^9/L Standard Deviation 43.848	-7.29 cells*10^9/L Standard Deviation 49.222	-5.37 cells*10^9/L Standard Deviation 46.084

PRIMARY outcome

Timeframe: Baseline, Weeks 6, 26, 39, and 52

Population: Safety Analysis Set: all participants who received any ABBV-951 infusion with available data

Samples for clinical laboratory tests were collected at study visits, and a certified central laboratory was used to process the samples and provide results.

Outcome measures

Measure	ABBV-951 Low Dose Subgroup n=130 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was \< 2530 mg of Foslevodopa/day were analyzed as the Low Dose Subgroup.	ABBV-951 High Dose Subgroup n=113 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was ≥ 2530 mg of Foslevodopa/day were analyzed as the High Dose Subgroup.	ABBV-951 All Participants n=243 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period.
Mean Corpuscular Hemoglobin (Hematology): Change From Baseline to End of Study Week 6	-0.09 picograms Standard Deviation 0.822	-0.15 picograms Standard Deviation 0.825	-0.12 picograms Standard Deviation 0.821
Mean Corpuscular Hemoglobin (Hematology): Change From Baseline to End of Study Week 26	-0.38 picograms Standard Deviation 1.033	0.05 picograms Standard Deviation 1.078	-0.18 picograms Standard Deviation 1.072
Mean Corpuscular Hemoglobin (Hematology): Change From Baseline to End of Study Week 39	-0.34 picograms Standard Deviation 1.205	-0.08 picograms Standard Deviation 0.978	-0.22 picograms Standard Deviation 1.114
Mean Corpuscular Hemoglobin (Hematology): Change From Baseline to End of Study Week 52	-0.36 picograms Standard Deviation 1.124	-0.07 picograms Standard Deviation 1.142	-0.23 picograms Standard Deviation 1.137

PRIMARY outcome

Timeframe: Baseline, Weeks 6, 26, 39, and 52

Population: Safety Analysis Set: all participants who received any ABBV-951 infusion with available data

Samples for clinical laboratory tests were collected at study visits, and a certified central laboratory was used to process the samples and provide results.

Outcome measures

Measure	ABBV-951 Low Dose Subgroup n=128 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was \< 2530 mg of Foslevodopa/day were analyzed as the Low Dose Subgroup.	ABBV-951 High Dose Subgroup n=113 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was ≥ 2530 mg of Foslevodopa/day were analyzed as the High Dose Subgroup.	ABBV-951 All Participants n=241 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period.
Mean Corpuscular Volume Concentration (MCHC) (Hematology): Change From Baseline to End of Study Week 6	2.15 g/L Standard Deviation 11.689	1.78 g/L Standard Deviation 10.870	1.97 g/L Standard Deviation 11.264
Mean Corpuscular Volume Concentration (MCHC) (Hematology): Change From Baseline to End of Study Week 26	-1.30 g/L Standard Deviation 14.844	2.17 g/L Standard Deviation 15.741	0.31 g/L Standard Deviation 15.306
Mean Corpuscular Volume Concentration (MCHC) (Hematology): Change From Baseline to End of Study Week 39	-2.13 g/L Standard Deviation 13.677	-2.64 g/L Standard Deviation 14.826	-2.37 g/L Standard Deviation 14.161
Mean Corpuscular Volume Concentration (MCHC) (Hematology): Change From Baseline to End of Study Week 52	-0.16 g/L Standard Deviation 12.609	0.18 g/L Standard Deviation 13.684	0.00 g/L Standard Deviation 13.074

PRIMARY outcome

Timeframe: Baseline, Weeks 6, 26, 39, and 52

Population: Safety Analysis Set: all participants who received any ABBV-951 infusion with available data

Samples for clinical laboratory tests were collected at study visits, and a certified central laboratory was used to process the samples and provide results.

Outcome measures

Measure	ABBV-951 Low Dose Subgroup n=131 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was \< 2530 mg of Foslevodopa/day were analyzed as the Low Dose Subgroup.	ABBV-951 High Dose Subgroup n=113 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was ≥ 2530 mg of Foslevodopa/day were analyzed as the High Dose Subgroup.	ABBV-951 All Participants n=244 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period.
Prothrombin Time (PT) (Hematology): Change From Baseline to End of Study Week 52	0.10 seconds Standard Deviation 0.889	-0.22 seconds Standard Deviation 3.703	-0.04 seconds Standard Deviation 2.483
Prothrombin Time (PT) (Hematology): Change From Baseline to End of Study Week 6	0.03 seconds Standard Deviation 0.480	-0.09 seconds Standard Deviation 2.556	-0.03 seconds Standard Deviation 1.803
Prothrombin Time (PT) (Hematology): Change From Baseline to End of Study Week 26	-0.08 seconds Standard Deviation 1.026	-0.36 seconds Standard Deviation 3.187	-0.20 seconds Standard Deviation 2.261
Prothrombin Time (PT) (Hematology): Change From Baseline to End of Study Week 39	0.10 seconds Standard Deviation 0.569	-0.21 seconds Standard Deviation 3.396	-0.03 seconds Standard Deviation 2.239

PRIMARY outcome

Timeframe: Baseline, Weeks 6, 26, 39, and 52

Population: Safety Analysis Set: all participants who received any ABBV-951 infusion with available data

Samples for clinical laboratory tests were collected at study visits, and a certified central laboratory was used to process the samples and provide results.

Outcome measures

Measure	ABBV-951 Low Dose Subgroup n=131 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was \< 2530 mg of Foslevodopa/day were analyzed as the Low Dose Subgroup.	ABBV-951 High Dose Subgroup n=113 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was ≥ 2530 mg of Foslevodopa/day were analyzed as the High Dose Subgroup.	ABBV-951 All Participants n=244 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period.
Activated Partial Thromboplastin Time (Hematology): Change From Baseline to End of Study Week 6	-0.27 seconds Standard Deviation 2.151	0.55 seconds Standard Deviation 2.483	0.13 seconds Standard Deviation 2.347
Activated Partial Thromboplastin Time (Hematology): Change From Baseline to End of Study Week 26	-0.02 seconds Standard Deviation 1.898	0.48 seconds Standard Deviation 1.932	0.20 seconds Standard Deviation 1.922
Activated Partial Thromboplastin Time (Hematology): Change From Baseline to End of Study Week 39	0.14 seconds Standard Deviation 1.556	0.67 seconds Standard Deviation 3.672	0.36 seconds Standard Deviation 2.661
Activated Partial Thromboplastin Time (Hematology): Change From Baseline to End of Study Week 52	-0.09 seconds Standard Deviation 2.156	0.88 seconds Standard Deviation 2.992	0.32 seconds Standard Deviation 2.573

PRIMARY outcome

Timeframe: Baseline, Weeks 6, 26, 39, and 52

Population: Safety Analysis Set: all participants who received any ABBV-951 infusion with available data

Samples for clinical laboratory tests were collected at study visits, and a certified central laboratory was used to process the samples and provide results.

Outcome measures

Measure	ABBV-951 Low Dose Subgroup n=131 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was \< 2530 mg of Foslevodopa/day were analyzed as the Low Dose Subgroup.	ABBV-951 High Dose Subgroup n=113 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was ≥ 2530 mg of Foslevodopa/day were analyzed as the High Dose Subgroup.	ABBV-951 All Participants n=244 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period.
Blood Urea Nitrogen (BUN) (Clinical Chemistry): Change From Baseline to End of Study Week 39	0.41 mmol/L Standard Deviation 1.852	0.05 mmol/L Standard Deviation 1.659	0.25 mmol/L Standard Deviation 1.773
Blood Urea Nitrogen (BUN) (Clinical Chemistry): Change From Baseline to End of Study Week 52	0.16 mmol/L Standard Deviation 1.836	0.15 mmol/L Standard Deviation 1.342	0.16 mmol/L Standard Deviation 1.636
Blood Urea Nitrogen (BUN) (Clinical Chemistry): Change From Baseline to End of Study Week 6	0.02 mmol/L Standard Deviation 1.348	-0.01 mmol/L Standard Deviation 1.560	0.00 mmol/L Standard Deviation 1.450
Blood Urea Nitrogen (BUN) (Clinical Chemistry): Change From Baseline to End of Study Week 26	0.21 mmol/L Standard Deviation 1.489	0.17 mmol/L Standard Deviation 1.600	0.19 mmol/L Standard Deviation 1.535

PRIMARY outcome

Timeframe: Baseline, Weeks 6, 26, 39, and 52

Population: Safety Analysis Set: all participants who received any ABBV-951 infusion with available data

Samples for clinical laboratory tests were collected at study visits, and a certified central laboratory was used to process the samples and provide results.

Outcome measures

Measure	ABBV-951 Low Dose Subgroup n=131 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was \< 2530 mg of Foslevodopa/day were analyzed as the Low Dose Subgroup.	ABBV-951 High Dose Subgroup n=113 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was ≥ 2530 mg of Foslevodopa/day were analyzed as the High Dose Subgroup.	ABBV-951 All Participants n=244 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period.
Creatinine (Clinical Chemistry): Change From Baseline to End of Study Week 6	-4.45 µmol/L Standard Deviation 9.227	-5.67 µmol/L Standard Deviation 10.725	-5.04 µmol/L Standard Deviation 9.968
Creatinine (Clinical Chemistry): Change From Baseline to End of Study Week 52	-4.78 µmol/L Standard Deviation 11.446	-5.21 µmol/L Standard Deviation 9.941	-4.96 µmol/L Standard Deviation 10.785
Creatinine (Clinical Chemistry): Change From Baseline to End of Study Week 26	-2.71 µmol/L Standard Deviation 10.478	-4.07 µmol/L Standard Deviation 12.074	-3.33 µmol/L Standard Deviation 11.213
Creatinine (Clinical Chemistry): Change From Baseline to End of Study Week 39	-1.47 µmol/L Standard Deviation 12.414	-4.02 µmol/L Standard Deviation 10.182	-2.58 µmol/L Standard Deviation 11.527

PRIMARY outcome

Timeframe: Baseline, Weeks 6, 26, 39, and 52

Population: Safety Analysis Set: all participants who received any ABBV-951 infusion with available data

Samples for clinical laboratory tests were collected at study visits, and a certified central laboratory was used to process the samples and provide results.

Outcome measures

Measure	ABBV-951 Low Dose Subgroup n=131 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was \< 2530 mg of Foslevodopa/day were analyzed as the Low Dose Subgroup.	ABBV-951 High Dose Subgroup n=113 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was ≥ 2530 mg of Foslevodopa/day were analyzed as the High Dose Subgroup.	ABBV-951 All Participants n=244 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period.
Creatine Phosphokinase (Clinical Chemistry): Change From Baseline to End of Study Week 6	2.52 U/L Standard Deviation 56.209	-11.01 U/L Standard Deviation 94.662	-4.01 U/L Standard Deviation 77.285
Creatine Phosphokinase (Clinical Chemistry): Change From Baseline to End of Study Week 52	30.39 U/L Standard Deviation 125.044	-16.55 U/L Standard Deviation 85.305	10.17 U/L Standard Deviation 111.783
Creatine Phosphokinase (Clinical Chemistry): Change From Baseline to End of Study Week 26	5.61 U/L Standard Deviation 51.627	-15.44 U/L Standard Deviation 62.435	-3.83 U/L Standard Deviation 57.480
Creatine Phosphokinase (Clinical Chemistry): Change From Baseline to End of Study Week 39	8.40 U/L Standard Deviation 96.021	-9.67 U/L Standard Deviation 75.655	0.66 U/L Standard Deviation 88.002

PRIMARY outcome

Timeframe: Baseline, Weeks 6, 26, 39, and 52

Population: Safety Analysis Set: all participants who received any ABBV-951 infusion with available data

Samples for clinical laboratory tests were collected at study visits, and a certified central laboratory was used to process the samples and provide results.

Outcome measures

Measure	ABBV-951 Low Dose Subgroup n=131 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was \< 2530 mg of Foslevodopa/day were analyzed as the Low Dose Subgroup.	ABBV-951 High Dose Subgroup n=113 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was ≥ 2530 mg of Foslevodopa/day were analyzed as the High Dose Subgroup.	ABBV-951 All Participants n=244 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period.
Total Bilirubin (Clinical Chemistry): Change From Baseline to End of Study Week 6	-0.85 µmol/L Standard Deviation 3.420	-0.15 µmol/L Standard Deviation 3.167	-0.51 µmol/L Standard Deviation 3.311
Total Bilirubin (Clinical Chemistry): Change From Baseline to End of Study Week 26	-0.43 µmol/L Standard Deviation 3.535	0.28 µmol/L Standard Deviation 2.814	-0.11 µmol/L Standard Deviation 3.240
Total Bilirubin (Clinical Chemistry): Change From Baseline to End of Study Week 39	-0.71 µmol/L Standard Deviation 2.881	0.31 µmol/L Standard Deviation 3.754	-0.27 µmol/L Standard Deviation 3.313
Total Bilirubin (Clinical Chemistry): Change From Baseline to End of Study Week 52	-0.30 µmol/L Standard Deviation 3.673	-0.15 µmol/L Standard Deviation 3.250	-0.24 µmol/L Standard Deviation 3.485

PRIMARY outcome

Timeframe: Baseline, Weeks 6, 26, 39, and 52

Population: Safety Analysis Set: all participants who received any ABBV-951 infusion with available data

Samples for clinical laboratory tests were collected at study visits, and a certified central laboratory was used to process the samples and provide results.

Outcome measures

Measure	ABBV-951 Low Dose Subgroup n=131 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was \< 2530 mg of Foslevodopa/day were analyzed as the Low Dose Subgroup.	ABBV-951 High Dose Subgroup n=113 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was ≥ 2530 mg of Foslevodopa/day were analyzed as the High Dose Subgroup.	ABBV-951 All Participants n=244 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period.
Serum Alanine Aminotransferase (Clinical Chemistry): Change From Baseline to End of Study Week 6	-8.94 U/L Standard Deviation 8.928	-11.28 U/L Standard Deviation 10.053	-10.07 U/L Standard Deviation 9.535
Serum Alanine Aminotransferase (Clinical Chemistry): Change From Baseline to End of Study Week 26	-8.95 U/L Standard Deviation 9.869	-11.66 U/L Standard Deviation 11.294	-10.16 U/L Standard Deviation 10.579
Serum Alanine Aminotransferase (Clinical Chemistry): Change From Baseline to End of Study Week 39	-9.70 U/L Standard Deviation 9.145	-10.09 U/L Standard Deviation 13.476	-9.87 U/L Standard Deviation 11.175
Serum Alanine Aminotransferase (Clinical Chemistry): Change From Baseline to End of Study Week 52	-9.37 U/L Standard Deviation 10.347	-12.11 U/L Standard Deviation 9.947	-10.56 U/L Standard Deviation 10.227

PRIMARY outcome

Timeframe: Baseline, Weeks 6, 26, 39, and 52

Population: Safety Analysis Set: all participants who received any ABBV-951 infusion with available data

Samples for clinical laboratory tests were collected at study visits, and a certified central laboratory was used to process the samples and provide results.

Outcome measures

Measure	ABBV-951 Low Dose Subgroup n=131 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was \< 2530 mg of Foslevodopa/day were analyzed as the Low Dose Subgroup.	ABBV-951 High Dose Subgroup n=113 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was ≥ 2530 mg of Foslevodopa/day were analyzed as the High Dose Subgroup.	ABBV-951 All Participants n=244 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period.
Serum Aspartate Aminotransferase (Clinical Chemistry): Change From Baseline to End of Study Week 6	-1.89 U/L Standard Deviation 4.881	-2.21 U/L Standard Deviation 6.163	-2.05 U/L Standard Deviation 5.524
Serum Aspartate Aminotransferase (Clinical Chemistry): Change From Baseline to End of Study Week 26	-0.69 U/L Standard Deviation 8.569	-2.56 U/L Standard Deviation 7.013	-1.52 U/L Standard Deviation 7.943
Serum Aspartate Aminotransferase (Clinical Chemistry): Change From Baseline to End of Study Week 39	-1.38 U/L Standard Deviation 6.714	-1.17 U/L Standard Deviation 7.036	-1.29 U/L Standard Deviation 6.827
Serum Aspartate Aminotransferase (Clinical Chemistry): Change From Baseline to End of Study Week 52	-0.81 U/L Standard Deviation 6.576	-0.82 U/L Standard Deviation 7.794	-0.81 U/L Standard Deviation 7.095

PRIMARY outcome

Timeframe: Baseline, Weeks 6, 26, 39, and 52

Population: Safety Analysis Set: all participants who received any ABBV-951 infusion with available data

Samples for clinical laboratory tests were collected at study visits, and a certified central laboratory was used to process the samples and provide results.

Outcome measures

Measure	ABBV-951 Low Dose Subgroup n=129 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was \< 2530 mg of Foslevodopa/day were analyzed as the Low Dose Subgroup.	ABBV-951 High Dose Subgroup n=109 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was ≥ 2530 mg of Foslevodopa/day were analyzed as the High Dose Subgroup.	ABBV-951 All Participants n=238 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period.
Serum Lactate Dehydrogenase (LDH) (Clinical Chemistry): Change From Baseline to End of Study Week 6	-6.57 U/L Standard Deviation 26.734	-8.58 U/L Standard Deviation 23.626	-7.55 U/L Standard Deviation 25.213
Serum Lactate Dehydrogenase (LDH) (Clinical Chemistry): Change From Baseline to End of Study Week 26	-1.66 U/L Standard Deviation 23.894	-4.91 U/L Standard Deviation 23.613	-3.14 U/L Standard Deviation 23.725
Serum Lactate Dehydrogenase (LDH) (Clinical Chemistry): Change From Baseline to End of Study Week 39	-2.17 U/L Standard Deviation 25.010	-2.02 U/L Standard Deviation 26.431	-2.10 U/L Standard Deviation 25.526
Serum Lactate Dehydrogenase (LDH) (Clinical Chemistry): Change From Baseline to End of Study Week 52	0.14 U/L Standard Deviation 22.788	3.32 U/L Standard Deviation 26.413	1.41 U/L Standard Deviation 24.237

PRIMARY outcome

Timeframe: Baseline, Weeks 6, 26, 39, and 52

Population: Safety Analysis Set: all participants who received any ABBV-951 infusion with available data

Samples for clinical laboratory tests were collected at study visits, and a certified central laboratory was used to process the samples and provide results.

Outcome measures

Measure	ABBV-951 Low Dose Subgroup n=131 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was \< 2530 mg of Foslevodopa/day were analyzed as the Low Dose Subgroup.	ABBV-951 High Dose Subgroup n=113 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was ≥ 2530 mg of Foslevodopa/day were analyzed as the High Dose Subgroup.	ABBV-951 All Participants n=244 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period.
Gamma-glutamyl Transferase (Clinical Chemistry): Change From Baseline to End of Study Week 39	-1.92 U/L Standard Deviation 10.860	-4.67 U/L Standard Deviation 12.516	-3.10 U/L Standard Deviation 11.631
Gamma-glutamyl Transferase (Clinical Chemistry): Change From Baseline to End of Study Week 52	1.69 U/L Standard Deviation 23.235	-3.09 U/L Standard Deviation 14.538	-0.37 U/L Standard Deviation 20.031
Gamma-glutamyl Transferase (Clinical Chemistry): Change From Baseline to End of Study Week 6	-1.07 U/L Standard Deviation 9.516	-3.13 U/L Standard Deviation 9.393	-2.06 U/L Standard Deviation 9.489
Gamma-glutamyl Transferase (Clinical Chemistry): Change From Baseline to End of Study Week 26	-1.47 U/L Standard Deviation 11.487	-5.02 U/L Standard Deviation 15.370	-3.07 U/L Standard Deviation 13.450

PRIMARY outcome

Timeframe: Baseline, Weeks 6, 26, 39, and 52

Population: Safety Analysis Set: all participants who received any ABBV-951 infusion with available data

Samples for clinical laboratory tests were collected at study visits, and a certified central laboratory was used to process the samples and provide results.

Outcome measures

Measure	ABBV-951 Low Dose Subgroup n=131 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was \< 2530 mg of Foslevodopa/day were analyzed as the Low Dose Subgroup.	ABBV-951 High Dose Subgroup n=113 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was ≥ 2530 mg of Foslevodopa/day were analyzed as the High Dose Subgroup.	ABBV-951 All Participants n=244 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period.
Alkaline Phosphatase (Clinical Chemistry): Change From Baseline to End of Study Week 6	-1.91 U/L Standard Deviation 12.394	-4.56 U/L Standard Deviation 12.340	-3.19 U/L Standard Deviation 12.408
Alkaline Phosphatase (Clinical Chemistry): Change From Baseline to End of Study Week 26	1.68 U/L Standard Deviation 18.995	-2.86 U/L Standard Deviation 14.157	-0.39 U/L Standard Deviation 17.051
Alkaline Phosphatase (Clinical Chemistry): Change From Baseline to End of Study Week 39	-2.28 U/L Standard Deviation 12.252	-5.02 U/L Standard Deviation 16.088	-3.46 U/L Standard Deviation 14.049
Alkaline Phosphatase (Clinical Chemistry): Change From Baseline to End of Study Week 52	0.55 U/L Standard Deviation 18.637	-1.54 U/L Standard Deviation 13.796	-0.35 U/L Standard Deviation 16.697

PRIMARY outcome

Timeframe: Baseline, Weeks 6, 26, 39, and 52

Population: Safety Analysis Set: all participants who received any ABBV-951 infusion with available data

Samples for clinical laboratory tests were collected at study visits, and a certified central laboratory was used to process the samples and provide results.

Outcome measures

Measure	ABBV-951 Low Dose Subgroup n=131 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was \< 2530 mg of Foslevodopa/day were analyzed as the Low Dose Subgroup.	ABBV-951 High Dose Subgroup n=113 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was ≥ 2530 mg of Foslevodopa/day were analyzed as the High Dose Subgroup.	ABBV-951 All Participants n=244 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period.
Sodium (Clinical Chemistry): Change From Baseline to End of Study Week 52	-0.55 mmol/L Standard Deviation 2.774	-0.84 mmol/L Standard Deviation 2.164	-0.67 mmol/L Standard Deviation 2.522
Sodium (Clinical Chemistry): Change From Baseline to End of Study Week 6	-0.52 mmol/L Standard Deviation 3.168	-1.06 mmol/L Standard Deviation 2.592	-0.78 mmol/L Standard Deviation 2.911
Sodium (Clinical Chemistry): Change From Baseline to End of Study Week 26	-0.35 mmol/L Standard Deviation 3.173	-1.26 mmol/L Standard Deviation 2.744	-0.76 mmol/L Standard Deviation 3.010
Sodium (Clinical Chemistry): Change From Baseline to End of Study Week 39	-0.90 mmol/L Standard Deviation 2.984	-0.68 mmol/L Standard Deviation 2.772	-0.81 mmol/L Standard Deviation 2.887

PRIMARY outcome

Timeframe: Baseline, Weeks 6, 26, 39, and 52

Population: Safety Analysis Set: all participants who received any ABBV-951 infusion with available data

Samples for clinical laboratory tests were collected at study visits, and a certified central laboratory was used to process the samples and provide results.

Outcome measures

Measure	ABBV-951 Low Dose Subgroup n=131 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was \< 2530 mg of Foslevodopa/day were analyzed as the Low Dose Subgroup.	ABBV-951 High Dose Subgroup n=113 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was ≥ 2530 mg of Foslevodopa/day were analyzed as the High Dose Subgroup.	ABBV-951 All Participants n=244 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period.
Potassium (Clinical Chemistry): Change From Baseline to End of Study Week 6	-0.02 mmol/L Standard Deviation 0.335	-0.08 mmol/L Standard Deviation 0.330	-0.05 mmol/L Standard Deviation 0.333
Potassium (Clinical Chemistry): Change From Baseline to End of Study Week 26	0.01 mmol/L Standard Deviation 0.367	0.00 mmol/L Standard Deviation 0.373	0.00 mmol/L Standard Deviation 0.368
Potassium (Clinical Chemistry): Change From Baseline to End of Study Week 39	-0.01 mmol/L Standard Deviation 0.389	-0.09 mmol/L Standard Deviation 0.382	-0.04 mmol/L Standard Deviation 0.387
Potassium (Clinical Chemistry): Change From Baseline to End of Study Week 52	-0.10 mmol/L Standard Deviation 0.369	-0.03 mmol/L Standard Deviation 0.338	-0.07 mmol/L Standard Deviation 0.357

PRIMARY outcome

Timeframe: Baseline, Weeks 6, 26, 39, and 52

Population: Safety Analysis Set: all participants who received any ABBV-951 infusion with available data

Samples for clinical laboratory tests were collected at study visits, and a certified central laboratory was used to process the samples and provide results.

Outcome measures

Measure	ABBV-951 Low Dose Subgroup n=131 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was \< 2530 mg of Foslevodopa/day were analyzed as the Low Dose Subgroup.	ABBV-951 High Dose Subgroup n=113 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was ≥ 2530 mg of Foslevodopa/day were analyzed as the High Dose Subgroup.	ABBV-951 All Participants n=244 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period.
Calcium (Clinical Chemistry): Change From Baseline to End of Study Week 26	-0.03 mmol/L Standard Deviation 0.080	-0.04 mmol/L Standard Deviation 0.091	-0.03 mmol/L Standard Deviation 0.085
Calcium (Clinical Chemistry): Change From Baseline to End of Study Week 6	-0.02 mmol/L Standard Deviation 0.079	-0.04 mmol/L Standard Deviation 0.086	-0.03 mmol/L Standard Deviation 0.083
Calcium (Clinical Chemistry): Change From Baseline to End of Study Week 39	-0.04 mmol/L Standard Deviation 0.091	-0.05 mmol/L Standard Deviation 0.087	-0.05 mmol/L Standard Deviation 0.089
Calcium (Clinical Chemistry): Change From Baseline to End of Study Week 52	-0.06 mmol/L Standard Deviation 0.084	-0.04 mmol/L Standard Deviation 0.092	-0.05 mmol/L Standard Deviation 0.088

PRIMARY outcome

Timeframe: Baseline, Weeks 6, 26, 39, and 52

Population: Safety Analysis Set: all participants who received any ABBV-951 infusion with available data

Samples for clinical laboratory tests were collected at study visits, and a certified central laboratory was used to process the samples and provide results.

Outcome measures

Measure	ABBV-951 Low Dose Subgroup n=131 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was \< 2530 mg of Foslevodopa/day were analyzed as the Low Dose Subgroup.	ABBV-951 High Dose Subgroup n=113 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was ≥ 2530 mg of Foslevodopa/day were analyzed as the High Dose Subgroup.	ABBV-951 All Participants n=244 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period.
Inorganic Phosphorus (Clinical Chemistry): Change From Baseline to End of Study Week 52	0.09 mmol/L Standard Deviation 0.169	0.08 mmol/L Standard Deviation 0.172	0.08 mmol/L Standard Deviation 0.170
Inorganic Phosphorus (Clinical Chemistry): Change From Baseline to End of Study Week 6	0.08 mmol/L Standard Deviation 0.173	0.08 mmol/L Standard Deviation 0.168	0.08 mmol/L Standard Deviation 0.170
Inorganic Phosphorus (Clinical Chemistry): Change From Baseline to End of Study Week 26	0.09 mmol/L Standard Deviation 0.182	0.09 mmol/L Standard Deviation 0.170	0.09 mmol/L Standard Deviation 0.176
Inorganic Phosphorus (Clinical Chemistry): Change From Baseline to End of Study Week 39	0.07 mmol/L Standard Deviation 0.165	0.08 mmol/L Standard Deviation 0.155	0.08 mmol/L Standard Deviation 0.160

PRIMARY outcome

Timeframe: Baseline, Weeks 6, 26, 39, and 52

Population: Safety Analysis Set: all participants who received any ABBV-951 infusion with available data

Samples for clinical laboratory tests were collected at study visits, and a certified central laboratory was used to process the samples and provide results.

Outcome measures

Measure	ABBV-951 Low Dose Subgroup n=131 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was \< 2530 mg of Foslevodopa/day were analyzed as the Low Dose Subgroup.	ABBV-951 High Dose Subgroup n=113 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was ≥ 2530 mg of Foslevodopa/day were analyzed as the High Dose Subgroup.	ABBV-951 All Participants n=244 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period.
Uric Acid (Clinical Chemistry): Change From Baseline to End of Study Week 6	-28.36 µmol/L Standard Deviation 51.219	-37.43 µmol/L Standard Deviation 37.302	-32.73 µmol/L Standard Deviation 45.163
Uric Acid (Clinical Chemistry): Change From Baseline to End of Study Week 26	-16.66 µmol/L Standard Deviation 60.922	-32.91 µmol/L Standard Deviation 34.446	-24.01 µmol/L Standard Deviation 51.163
Uric Acid (Clinical Chemistry): Change From Baseline to End of Study Week 39	-13.55 µmol/L Standard Deviation 57.830	-35.80 µmol/L Standard Deviation 40.965	-23.18 µmol/L Standard Deviation 52.213
Uric Acid (Clinical Chemistry): Change From Baseline to End of Study Week 52	-15.27 µmol/L Standard Deviation 56.459	-31.23 µmol/L Standard Deviation 29.780	-22.15 µmol/L Standard Deviation 47.380

PRIMARY outcome

Timeframe: Baseline, Weeks 6, 26, 39, and 52

Population: Safety Analysis Set: all participants who received any ABBV-951 infusion with available data

Samples for clinical laboratory tests were collected at study visits, and a certified central laboratory was used to process the samples and provide results.

Outcome measures

Measure	ABBV-951 Low Dose Subgroup n=131 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was \< 2530 mg of Foslevodopa/day were analyzed as the Low Dose Subgroup.	ABBV-951 High Dose Subgroup n=113 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was ≥ 2530 mg of Foslevodopa/day were analyzed as the High Dose Subgroup.	ABBV-951 All Participants n=244 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period.
Total Cholesterol (Clinical Chemistry): Change From Baseline to End of Study Week 6	-0.37 mmol/L Standard Deviation 0.688	-0.57 mmol/L Standard Deviation 0.556	-0.47 mmol/L Standard Deviation 0.634
Total Cholesterol (Clinical Chemistry): Change From Baseline to End of Study Week 26	-0.19 mmol/L Standard Deviation 0.657	-0.31 mmol/L Standard Deviation 0.661	-0.25 mmol/L Standard Deviation 0.659
Total Cholesterol (Clinical Chemistry): Change From Baseline to End of Study Week 39	-0.33 mmol/L Standard Deviation 0.565	-0.41 mmol/L Standard Deviation 0.552	-0.36 mmol/L Standard Deviation 0.559
Total Cholesterol (Clinical Chemistry): Change From Baseline to End of Study Week 52	-0.31 mmol/L Standard Deviation 0.660	-0.25 mmol/L Standard Deviation 0.594	-0.29 mmol/L Standard Deviation 0.630

PRIMARY outcome

Timeframe: Baseline, Weeks 6, 26, 39, and 52

Population: Safety Analysis Set: all participants who received any ABBV-951 infusion with available data

Samples for clinical laboratory tests were collected at study visits, and a certified central laboratory was used to process the samples and provide results.

Outcome measures

Measure	ABBV-951 Low Dose Subgroup n=131 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was \< 2530 mg of Foslevodopa/day were analyzed as the Low Dose Subgroup.	ABBV-951 High Dose Subgroup n=113 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was ≥ 2530 mg of Foslevodopa/day were analyzed as the High Dose Subgroup.	ABBV-951 All Participants n=244 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period.
Albumin (Clinical Chemistry): Change From Baseline to End of Study Week 6	-1.65 g/L Standard Deviation 2.782	-1.95 g/L Standard Deviation 2.885	-1.79 g/L Standard Deviation 2.829
Albumin (Clinical Chemistry): Change From Baseline to End of Study Week 26	-1.31 g/L Standard Deviation 2.541	-1.14 g/L Standard Deviation 2.558	-1.23 g/L Standard Deviation 2.541
Albumin (Clinical Chemistry): Change From Baseline to End of Study Week 39	-1.75 g/L Standard Deviation 2.782	-1.56 g/L Standard Deviation 2.507	-1.67 g/L Standard Deviation 2.658
Albumin (Clinical Chemistry): Change From Baseline to End of Study Week 52	-1.96 g/L Standard Deviation 2.949	-1.02 g/L Standard Deviation 3.205	-1.55 g/L Standard Deviation 3.086

PRIMARY outcome

Timeframe: Baseline, Weeks 6, 26, 39, and 52

Population: Safety Analysis Set: all participants who received any ABBV-951 infusion with available data

Samples for clinical laboratory tests were collected at study visits, and a certified central laboratory was used to process the samples and provide results.

Outcome measures

Measure	ABBV-951 Low Dose Subgroup n=131 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was \< 2530 mg of Foslevodopa/day were analyzed as the Low Dose Subgroup.	ABBV-951 High Dose Subgroup n=113 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was ≥ 2530 mg of Foslevodopa/day were analyzed as the High Dose Subgroup.	ABBV-951 All Participants n=244 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period.
Glucose (Clinical Chemistry): Change From Baseline to End of Study Week 6	-0.39 mmol/L Standard Deviation 1.186	-0.39 mmol/L Standard Deviation 1.438	-0.39 mmol/L Standard Deviation 1.311
Glucose (Clinical Chemistry): Change From Baseline to End of Study Week 26	-0.37 mmol/L Standard Deviation 1.271	-0.14 mmol/L Standard Deviation 1.486	-0.27 mmol/L Standard Deviation 1.373
Glucose (Clinical Chemistry): Change From Baseline to End of Study Week 39	-0.33 mmol/L Standard Deviation 1.181	-0.60 mmol/L Standard Deviation 1.327	-0.45 mmol/L Standard Deviation 1.249
Glucose (Clinical Chemistry): Change From Baseline to End of Study Week 52	-0.32 mmol/L Standard Deviation 1.917	-0.55 mmol/L Standard Deviation 1.479	-0.42 mmol/L Standard Deviation 1.740

PRIMARY outcome

Timeframe: Baseline, Weeks 6, 26, 39, and 52

Population: Safety Analysis Set: all participants who received any ABBV-951 infusion with available data

Samples for clinical laboratory tests were collected at study visits, and a certified central laboratory was used to process the samples and provide results.

Outcome measures

Measure	ABBV-951 Low Dose Subgroup n=130 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was \< 2530 mg of Foslevodopa/day were analyzed as the Low Dose Subgroup.	ABBV-951 High Dose Subgroup n=113 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was ≥ 2530 mg of Foslevodopa/day were analyzed as the High Dose Subgroup.	ABBV-951 All Participants n=243 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period.
Sodium Bicarbonate/CO2 (Clinical Chemistry): Change From Baseline to End of Study Week 6	1.19 mmol/L Standard Deviation 2.372	0.97 mmol/L Standard Deviation 2.518	1.09 mmol/L Standard Deviation 2.440
Sodium Bicarbonate/CO2 (Clinical Chemistry): Change From Baseline to End of Study Week 26	0.77 mmol/L Standard Deviation 2.418	0.28 mmol/L Standard Deviation 2.744	0.55 mmol/L Standard Deviation 2.574
Sodium Bicarbonate/CO2 (Clinical Chemistry): Change From Baseline to End of Study Week 39	0.90 mmol/L Standard Deviation 2.240	0.63 mmol/L Standard Deviation 2.874	0.78 mmol/L Standard Deviation 2.522
Sodium Bicarbonate/CO2 (Clinical Chemistry): Change From Baseline to End of Study Week 52	0.78 mmol/L Standard Deviation 2.374	0.57 mmol/L Standard Deviation 2.304	0.69 mmol/L Standard Deviation 2.337

PRIMARY outcome

Timeframe: Baseline, Weeks 6, 26, 39, and 52

Population: Safety Analysis Set: all participants who received any ABBV-951 infusion with available data

Samples for clinical laboratory tests were collected at study visits, and a certified central laboratory was used to process the samples and provide results.

Outcome measures

Measure	ABBV-951 Low Dose Subgroup n=131 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was \< 2530 mg of Foslevodopa/day were analyzed as the Low Dose Subgroup.	ABBV-951 High Dose Subgroup n=113 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was ≥ 2530 mg of Foslevodopa/day were analyzed as the High Dose Subgroup.	ABBV-951 All Participants n=244 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period.
Magnesium (Clinical Chemistry): Change From Baseline to End of Study Week 6	-0.03 mmol/L Standard Deviation 0.067	-0.03 mmol/L Standard Deviation 0.058	-0.03 mmol/L Standard Deviation 0.063
Magnesium (Clinical Chemistry): Change From Baseline to End of Study Week 26	-0.03 mmol/L Standard Deviation 0.064	-0.02 mmol/L Standard Deviation 0.062	-0.02 mmol/L Standard Deviation 0.063
Magnesium (Clinical Chemistry): Change From Baseline to End of Study Week 39	-0.02 mmol/L Standard Deviation 0.076	-0.01 mmol/L Standard Deviation 0.073	-0.02 mmol/L Standard Deviation 0.075
Magnesium (Clinical Chemistry): Change From Baseline to End of Study Week 52	-0.03 mmol/L Standard Deviation 0.078	-0.01 mmol/L Standard Deviation 0.057	-0.02 mmol/L Standard Deviation 0.070

PRIMARY outcome

Timeframe: Baseline, Weeks 6, 26, 39, and 52

Population: Safety Analysis Set: all participants who received any ABBV-951 infusion with available data

Samples for clinical laboratory tests were collected at study visits, and a certified central laboratory was used to process the samples and provide results.

Outcome measures

Measure	ABBV-951 Low Dose Subgroup n=1 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was \< 2530 mg of Foslevodopa/day were analyzed as the Low Dose Subgroup.	ABBV-951 High Dose Subgroup n=1 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was ≥ 2530 mg of Foslevodopa/day were analyzed as the High Dose Subgroup.	ABBV-951 All Participants n=2 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period.
Creatinine Clearance (Clinical Chemistry): Change From Baseline to End of Study Week 6	-0.08 mL/sec/1.73m^2	0.00 mL/sec/1.73m^2	-0.04 mL/sec/1.73m^2 Standard Deviation 0.059
Creatinine Clearance (Clinical Chemistry): Change From Baseline to End of Study Week 26	—	-0.17 mL/sec/1.73m^2	-0.17 mL/sec/1.73m^2

PRIMARY outcome

Timeframe: Baseline, Weeks 6, 26, and 52

Population: Safety Analysis Set: all participants who received any ABBV-951 infusion with available data

Samples for clinical laboratory tests were collected at study visits, and a certified central laboratory was used to process the samples and provide results.

Outcome measures

Measure	ABBV-951 Low Dose Subgroup n=131 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was \< 2530 mg of Foslevodopa/day were analyzed as the Low Dose Subgroup.	ABBV-951 High Dose Subgroup n=113 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was ≥ 2530 mg of Foslevodopa/day were analyzed as the High Dose Subgroup.	ABBV-951 All Participants n=244 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period.
Homocysteine (Clinical Chemistry): Change From Baseline to End of Study Week 6	3.07 µmol/L Standard Deviation 5.301	6.70 µmol/L Standard Deviation 11.040	4.79 µmol/L Standard Deviation 8.692
Homocysteine (Clinical Chemistry): Change From Baseline to End of Study Week 26	4.22 µmol/L Standard Deviation 7.549	6.69 µmol/L Standard Deviation 6.306	5.32 µmol/L Standard Deviation 7.106
Homocysteine (Clinical Chemistry): Change From Baseline to End of Study Week 52	4.88 µmol/L Standard Deviation 6.103	7.24 µmol/L Standard Deviation 8.687	5.86 µmol/L Standard Deviation 7.351

PRIMARY outcome

Timeframe: Baseline, Weeks 6, 26, and 52

Population: Safety Analysis Set: all participants who received any ABBV-951 infusion with available data

Samples for clinical laboratory tests were collected at study visits, and a certified central laboratory was used to process the samples and provide results.

Outcome measures

Measure	ABBV-951 Low Dose Subgroup n=131 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was \< 2530 mg of Foslevodopa/day were analyzed as the Low Dose Subgroup.	ABBV-951 High Dose Subgroup n=113 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was ≥ 2530 mg of Foslevodopa/day were analyzed as the High Dose Subgroup.	ABBV-951 All Participants n=244 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period.
Vitamin B6 (Clinical Chemistry): Change From Baseline to End of Study Week 6	0.30 nmol/L Standard Deviation 129.306	4.68 nmol/L Standard Deviation 87.199	2.38 nmol/L Standard Deviation 111.069
Vitamin B6 (Clinical Chemistry): Change From Baseline to End of Study Week 26	-4.50 nmol/L Standard Deviation 89.013	14.10 nmol/L Standard Deviation 103.462	3.86 nmol/L Standard Deviation 95.865
Vitamin B6 (Clinical Chemistry): Change From Baseline to End of Study Week 52	-0.32 nmol/L Standard Deviation 124.059	44.30 nmol/L Standard Deviation 124.456	18.95 nmol/L Standard Deviation 125.703

PRIMARY outcome

Timeframe: Baseline, Weeks 6, 26, and 52

Population: Safety Analysis Set: all participants who received any ABBV-951 infusion with available data

Samples for clinical laboratory tests were collected at study visits, and a certified central laboratory was used to process the samples and provide results.

Outcome measures

Measure	ABBV-951 Low Dose Subgroup n=131 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was \< 2530 mg of Foslevodopa/day were analyzed as the Low Dose Subgroup.	ABBV-951 High Dose Subgroup n=113 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was ≥ 2530 mg of Foslevodopa/day were analyzed as the High Dose Subgroup.	ABBV-951 All Participants n=244 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period.
Vitamin B12 (Clinical Chemistry): Change From Baseline to End of Study Week 6	-229.58 pmol/L Standard Deviation 1349.008	-206.30 pmol/L Standard Deviation 2217.016	-218.53 pmol/L Standard Deviation 1808.859
Vitamin B12 (Clinical Chemistry): Change From Baseline to End of Study Week 26	-147.38 pmol/L Standard Deviation 845.662	-143.30 pmol/L Standard Deviation 1033.488	-145.53 pmol/L Standard Deviation 931.955
Vitamin B12 (Clinical Chemistry): Change From Baseline to End of Study Week 52	-268.44 pmol/L Standard Deviation 1684.785	-212.84 pmol/L Standard Deviation 1096.656	-244.98 pmol/L Standard Deviation 1460.902

PRIMARY outcome

Timeframe: Baseline, Weeks 6, 26, 39, and 52

Population: Safety Analysis Set: all participants who received any ABBV-951 infusion with available data

Samples for clinical laboratory tests were collected at study visits, and a certified central laboratory was used to process the samples and provide results.

Outcome measures

Measure	ABBV-951 Low Dose Subgroup n=131 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was \< 2530 mg of Foslevodopa/day were analyzed as the Low Dose Subgroup.	ABBV-951 High Dose Subgroup n=113 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was ≥ 2530 mg of Foslevodopa/day were analyzed as the High Dose Subgroup.	ABBV-951 All Participants n=244 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period.
pH (Urinalysis): Change From Baseline to End of Study Week 6	0.07 no units Standard Deviation 0.601	0.19 no units Standard Deviation 0.575	0.13 no units Standard Deviation 0.590
pH (Urinalysis): Change From Baseline to End of Study Week 26	0.20 no units Standard Deviation 0.537	0.24 no units Standard Deviation 0.560	0.22 no units Standard Deviation 0.546
pH (Urinalysis): Change From Baseline to End of Study Week 39	0.13 no units Standard Deviation 0.566	0.31 no units Standard Deviation 0.617	0.21 no units Standard Deviation 0.594
pH (Urinalysis): Change From Baseline to End of Study Week 52	0.18 no units Standard Deviation 0.682	0.20 no units Standard Deviation 0.537	0.19 no units Standard Deviation 0.620

PRIMARY outcome

Timeframe: Baseline, Weeks 6, 26, 39, and 52

Population: Safety Analysis Set: all participants who received any ABBV-951 infusion with available data

Samples for clinical laboratory tests were collected at study visits, and a certified central laboratory was used to process the samples and provide results.

Outcome measures

Measure	ABBV-951 Low Dose Subgroup n=131 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was \< 2530 mg of Foslevodopa/day were analyzed as the Low Dose Subgroup.	ABBV-951 High Dose Subgroup n=113 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was ≥ 2530 mg of Foslevodopa/day were analyzed as the High Dose Subgroup.	ABBV-951 All Participants n=244 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period.
Specific Gravity (Urinalysis): Change From Baseline to End of Study Week 6	0.00 No units Standard Deviation 0.009	0.00 No units Standard Deviation 0.007	0.00 No units Standard Deviation 0.008
Specific Gravity (Urinalysis): Change From Baseline to End of Study Week 26	0.00 No units Standard Deviation 0.009	0.00 No units Standard Deviation 0.009	0.00 No units Standard Deviation 0.009
Specific Gravity (Urinalysis): Change From Baseline to End of Study Week 39	0.00 No units Standard Deviation 0.009	0.00 No units Standard Deviation 0.009	0.00 No units Standard Deviation 0.009
Specific Gravity (Urinalysis): Change From Baseline to End of Study Week 52	0.00 No units Standard Deviation 0.010	0.00 No units Standard Deviation 0.009	0.00 No units Standard Deviation 0.009

PRIMARY outcome

Timeframe: Baseline, Weeks 1, 6, 26, and 52 (orthostatic and standing); Baseline, Weeks 2, 4, 13, and 39 (supine)

Population: Safety Analysis Set: all participants who received any ABBV-951 infusion with available data

Orthostatic blood pressure was measured after the participant had been supine (lying down with their face up) for at least 5 minutes and then, after the participant had been standing for 2 minutes. When vital sign measurements were scheduled at the same time as a blood collection, vital sign measurements were obtained prior to blood collection.

Outcome measures

Measure	ABBV-951 Low Dose Subgroup n=128 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was \< 2530 mg of Foslevodopa/day were analyzed as the Low Dose Subgroup.	ABBV-951 High Dose Subgroup n=112 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was ≥ 2530 mg of Foslevodopa/day were analyzed as the High Dose Subgroup.	ABBV-951 All Participants n=240 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period.
Orthostatic Systolic Blood Pressure (Vital Signs): Change From Baseline to End of Study Week 6- standing	-2.9 mmHg Standard Deviation 18.32	-3.1 mmHg Standard Deviation 25.89	-3.0 mmHg Standard Deviation 22.19
Orthostatic Systolic Blood Pressure (Vital Signs): Change From Baseline to End of Study Week 1- orthostatic	-1.5 mmHg Standard Deviation 12.00	3.5 mmHg Standard Deviation 16.01	0.9 mmHg Standard Deviation 14.22
Orthostatic Systolic Blood Pressure (Vital Signs): Change From Baseline to End of Study Week 6- orthostatic	-1.5 mmHg Standard Deviation 11.85	2.6 mmHg Standard Deviation 17.33	0.5 mmHg Standard Deviation 14.83
Orthostatic Systolic Blood Pressure (Vital Signs): Change From Baseline to End of Study Week 26- orthostatic	-2.4 mmHg Standard Deviation 16.25	-0.3 mmHg Standard Deviation 14.38	-1.4 mmHg Standard Deviation 15.38
Orthostatic Systolic Blood Pressure (Vital Signs): Change From Baseline to End of Study Week 52- orthostatic	-1.3 mmHg Standard Deviation 14.59	0.7 mmHg Standard Deviation 13.75	-0.4 mmHg Standard Deviation 14.19
Orthostatic Systolic Blood Pressure (Vital Signs): Change From Baseline to End of Study Week 26- standing	-4.7 mmHg Standard Deviation 19.23	-4.0 mmHg Standard Deviation 21.01	-4.4 mmHg Standard Deviation 20.00
Orthostatic Systolic Blood Pressure (Vital Signs): Change From Baseline to End of Study Week 1- standing	-2.3 mmHg Standard Deviation 17.05	-1.3 mmHg Standard Deviation 25.50	-1.9 mmHg Standard Deviation 21.35
Orthostatic Systolic Blood Pressure (Vital Signs): Change From Baseline to End of Study Week 52- standing	-3.9 mmHg Standard Deviation 19.81	-1.5 mmHg Standard Deviation 20.91	-2.8 mmHg Standard Deviation 20.26
Orthostatic Systolic Blood Pressure (Vital Signs): Change From Baseline to End of Study Week 2- supine	-1.0 mmHg Standard Deviation 16.75	-4.5 mmHg Standard Deviation 21.94	-2.7 mmHg Standard Deviation 19.42
Orthostatic Systolic Blood Pressure (Vital Signs): Change From Baseline to End of Study Week 4- supine	-1.2 mmHg Standard Deviation 16.67	-6.7 mmHg Standard Deviation 22.99	-3.8 mmHg Standard Deviation 20.05
Orthostatic Systolic Blood Pressure (Vital Signs): Change From Baseline to End of Study Week 13- supine	-4.0 mmHg Standard Deviation 18.34	-1.8 mmHg Standard Deviation 24.89	-3.2 mmHg Standard Deviation 20.75
Orthostatic Systolic Blood Pressure (Vital Signs): Change From Baseline to End of Study Week 39- supine	-1.7 mmHg Standard Deviation 19.12	-1.8 mmHg Standard Deviation 22.08	-1.7 mmHg Standard Deviation 20.47

PRIMARY outcome

Timeframe: Baseline, Weeks 1, 6, 26, and 52 (orthostatic and standing); Baseline, Weeks 2, 4, 13, and 39 (supine)

Population: Safety Analysis Set: all participants who received any ABBV-951 infusion with available data

Orthostatic blood pressure was measured after the participant had been supine (lying down with their face up) for at least 5 minutes and then, after the participant had been standing for 2 minutes. When vital sign measurements were scheduled at the same time as a blood collection, vital sign measurements were obtained prior to blood collection.

Outcome measures

Measure	ABBV-951 Low Dose Subgroup n=128 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was \< 2530 mg of Foslevodopa/day were analyzed as the Low Dose Subgroup.	ABBV-951 High Dose Subgroup n=112 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was ≥ 2530 mg of Foslevodopa/day were analyzed as the High Dose Subgroup.	ABBV-951 All Participants n=240 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period.
Orthostatic Diastolic Blood Pressure (Vital Signs): Change From Baseline to End of Study Week 1- orthostatic	-1.9 mmHg Standard Deviation 10.61	-0.7 mmHg Standard Deviation 13.27	-1.3 mmHg Standard Deviation 11.92
Orthostatic Diastolic Blood Pressure (Vital Signs): Change From Baseline to End of Study Week 6- orthostatic	0.0 mmHg Standard Deviation 10.91	-0.6 mmHg Standard Deviation 10.00	-0.3 mmHg Standard Deviation 10.46
Orthostatic Diastolic Blood Pressure (Vital Signs): Change From Baseline to End of Study Week 26- orthostatic	-1.7 mmHg Standard Deviation 12.99	0.3 mmHg Standard Deviation 10.16	-0.7 mmHg Standard Deviation 11.75
Orthostatic Diastolic Blood Pressure (Vital Signs): Change From Baseline to End of Study Week 52- orthostatic	-1.5 mmHg Standard Deviation 10.44	0.8 mmHg Standard Deviation 11.42	-0.4 mmHg Standard Deviation 10.91
Orthostatic Diastolic Blood Pressure (Vital Signs): Change From Baseline to End of Study Week 1- standing	-2.6 mmHg Standard Deviation 12.00	-2.1 mmHg Standard Deviation 13.87	-2.4 mmHg Standard Deviation 12.88
Orthostatic Diastolic Blood Pressure (Vital Signs): Change From Baseline to End of Study Week 6- standing	-0.8 mmHg Standard Deviation 12.27	-2.2 mmHg Standard Deviation 14.76	-1.5 mmHg Standard Deviation 13.50
Orthostatic Diastolic Blood Pressure (Vital Signs): Change From Baseline to End of Study Week 26- standing	-4.0 mmHg Standard Deviation 12.20	-1.2 mmHg Standard Deviation 14.67	-2.7 mmHg Standard Deviation 13.42
Orthostatic Diastolic Blood Pressure (Vital Signs): Change From Baseline to End of Study Week 52- standing	-1.7 mmHg Standard Deviation 12.55	1.1 mmHg Standard Deviation 12.01	-0.4 mmHg Standard Deviation 12.34
Orthostatic Diastolic Blood Pressure (Vital Signs): Change From Baseline to End of Study Week 2- supine	-1.1 mmHg Standard Deviation 12.46	-1.3 mmHg Standard Deviation 13.46	-1.2 mmHg Standard Deviation 12.91
Orthostatic Diastolic Blood Pressure (Vital Signs): Change From Baseline to End of Study Week 4- supine	-1.4 mmHg Standard Deviation 12.06	-2.1 mmHg Standard Deviation 12.80	-1.7 mmHg Standard Deviation 12.38
Orthostatic Diastolic Blood Pressure (Vital Signs): Change From Baseline to End of Study Week 13- supine	-2.6 mmHg Standard Deviation 12.52	-0.5 mmHg Standard Deviation 9.59	-1.8 mmHg Standard Deviation 11.46
Orthostatic Diastolic Blood Pressure (Vital Signs): Change From Baseline to End of Study Week 39- supine	0.2 mmHg Standard Deviation 12.16	0.2 mmHg Standard Deviation 12.77	0.2 mmHg Standard Deviation 12.40

PRIMARY outcome

Timeframe: Baseline, Weeks 1, 6, 26, and 52 (orthostatic and standing); Baseline, Weeks 2, 4, 13, and 39 (supine)

Population: Safety Analysis Set: all participants who received any ABBV-951 infusion with available data

Orthostatic pulse rate was measured after the participant had been supine (lying down with their face up) for at least 5 minutes and then, after the participant had been standing for 2 minutes. When vital sign measurements were scheduled at the same time as a blood collection, vital sign measurements were obtained prior to blood collection.

Outcome measures

Measure	ABBV-951 Low Dose Subgroup n=128 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was \< 2530 mg of Foslevodopa/day were analyzed as the Low Dose Subgroup.	ABBV-951 High Dose Subgroup n=112 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was ≥ 2530 mg of Foslevodopa/day were analyzed as the High Dose Subgroup.	ABBV-951 All Participants n=240 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period.
Orthostatic Pulse Rate (Vital Signs): Change From Baseline to End of Study Week 4- supine	-2.6 beats/minute Standard Deviation 10.06	-3.3 beats/minute Standard Deviation 12.60	-3.0 beats/minute Standard Deviation 11.31
Orthostatic Pulse Rate (Vital Signs): Change From Baseline to End of Study Week 13- supine	1.1 beats/minute Standard Deviation 11.72	-4.8 beats/minute Standard Deviation 7.60	-1.1 beats/minute Standard Deviation 10.68
Orthostatic Pulse Rate (Vital Signs): Change From Baseline to End of Study Week 39- supine	-3.7 beats/minute Standard Deviation 11.76	-3.2 beats/minute Standard Deviation 11.16	-3.4 beats/minute Standard Deviation 11.45
Orthostatic Pulse Rate (Vital Signs): Change From Baseline to End of Study Week 1- orthostatic	-1.5 beats/minute Standard Deviation 8.49	-1.8 beats/minute Standard Deviation 10.49	-1.6 beats/minute Standard Deviation 9.46
Orthostatic Pulse Rate (Vital Signs): Change From Baseline to End of Study Week 6- orthostatic	-0.5 beats/minute Standard Deviation 10.86	0.2 beats/minute Standard Deviation 10.16	-0.1 beats/minute Standard Deviation 10.51
Orthostatic Pulse Rate (Vital Signs): Change From Baseline to End of Study Week 26- orthostatic	-0.9 beats/minute Standard Deviation 8.90	0.3 beats/minute Standard Deviation 9.32	-0.4 beats/minute Standard Deviation 9.08
Orthostatic Pulse Rate (Vital Signs): Change From Baseline to End of Study Week 52- orthostatic	0.5 beats/minute Standard Deviation 9.72	-0.5 beats/minute Standard Deviation 8.55	0.0 beats/minute Standard Deviation 9.19
Orthostatic Pulse Rate (Vital Signs): Change From Baseline to End of Study Week 1- standing	-5.1 beats/minute Standard Deviation 11.43	-2.6 beats/minute Standard Deviation 12.50	-3.9 beats/minute Standard Deviation 11.98
Orthostatic Pulse Rate (Vital Signs): Change From Baseline to End of Study Week 6- standing	-3.1 beats/minute Standard Deviation 12.45	-3.0 beats/minute Standard Deviation 12.23	-3.1 beats/minute Standard Deviation 12.31
Orthostatic Pulse Rate (Vital Signs): Change From Baseline to End of Study Week 26- standing	-2.9 beats/minute Standard Deviation 12.29	-2.4 beats/minute Standard Deviation 12.43	-2.7 beats/minute Standard Deviation 12.31
Orthostatic Pulse Rate (Vital Signs): Change From Baseline to End of Study Week 52- standing	-3.8 beats/minute Standard Deviation 12.88	-4.3 beats/minute Standard Deviation 11.56	-4.0 beats/minute Standard Deviation 12.27
Orthostatic Pulse Rate (Vital Signs): Change From Baseline to End of Study Week 2- supine	-3.3 beats/minute Standard Deviation 10.05	-0.6 beats/minute Standard Deviation 11.10	-2.0 beats/minute Standard Deviation 10.62

PRIMARY outcome

Timeframe: Baseline, Day 1 (postdose), Weeks 6 and 52

Population: Safety Analysis Set: all participants who received any ABBV-951 infusion with available data

12-lead electrocardiograms (ECGs) were recorded at study visits after the participant had been supine for at least 5 minutes. Participants were instructed to remain stationary (no talking, laughing, deep breathing, sleeping, or swallowing) for approximately 10 seconds during the ECG recording. When an ECG was recorded at a time near that of a blood collection, the ECG was obtained prior to the blood collection. ECGs on Day 1 were recorded after initiation of the continuous subcutaneous infusion (CSCI) of ABBV-951 prior to the end of the study visit.

Outcome measures

Measure	ABBV-951 Low Dose Subgroup n=131 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was \< 2530 mg of Foslevodopa/day were analyzed as the Low Dose Subgroup.	ABBV-951 High Dose Subgroup n=113 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was ≥ 2530 mg of Foslevodopa/day were analyzed as the High Dose Subgroup.	ABBV-951 All Participants n=244 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period.
Electrocardiogram (ECG) Mean Heart Rate: Change From Baseline to End of Study Day 1 (postdose)	2.1 beats/minute Standard Deviation 9.51	2.2 beats/minute Standard Deviation 9.76	2.1 beats/minute Standard Deviation 9.61
Electrocardiogram (ECG) Mean Heart Rate: Change From Baseline to End of Study Week 6	-2.3 beats/minute Standard Deviation 8.60	-2.2 beats/minute Standard Deviation 10.28	-2.2 beats/minute Standard Deviation 9.40
Electrocardiogram (ECG) Mean Heart Rate: Change From Baseline to End of Study Week 52	-3.7 beats/minute Standard Deviation 9.51	-0.7 beats/minute Standard Deviation 11.36	-2.3 beats/minute Standard Deviation 10.44

PRIMARY outcome

Timeframe: Baseline, Day 1 (postdose), Weeks 6 and 52

Population: Safety Analysis Set: all participants who received any ABBV-951 infusion with available data

12-lead electrocardiograms (ECGs) were recorded at study visits after the participant had been supine for at least 5 minutes. Participants were instructed to remain stationary (no talking, laughing, deep breathing, sleeping, or swallowing) for approximately 10 seconds during the ECG recording. When an ECG was recorded at a time near that of a blood collection, the ECG was obtained prior to the blood collection. ECGs on Day 1 were recorded after initiation of the continuous subcutaneous infusion (CSCI) of ABBV-951 prior to the end of the study visit.

Outcome measures

Measure	ABBV-951 Low Dose Subgroup n=130 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was \< 2530 mg of Foslevodopa/day were analyzed as the Low Dose Subgroup.	ABBV-951 High Dose Subgroup n=107 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was ≥ 2530 mg of Foslevodopa/day were analyzed as the High Dose Subgroup.	ABBV-951 All Participants n=237 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period.
Electrocardiogram (ECG) Aggregate PR Interval: Change From Baseline to End of Study Day 1 (postdose)	0.4 milliseconds Standard Deviation 14.08	-0.1 milliseconds Standard Deviation 13.76	0.2 milliseconds Standard Deviation 13.91
Electrocardiogram (ECG) Aggregate PR Interval: Change From Baseline to End of Study Week 6	0.5 milliseconds Standard Deviation 13.97	1.1 milliseconds Standard Deviation 16.84	0.8 milliseconds Standard Deviation 15.31
Electrocardiogram (ECG) Aggregate PR Interval: Change From Baseline to End of Study Week 52	1.5 milliseconds Standard Deviation 12.48	-5.8 milliseconds Standard Deviation 20.54	-1.6 milliseconds Standard Deviation 16.75

PRIMARY outcome

Timeframe: Baseline, Day 1 (postdose), Weeks 6 and 52

Population: Safety Analysis Set: all participants who received any ABBV-951 infusion with available data

12-lead electrocardiograms (ECGs) were recorded at study visits after the participant had been supine for at least 5 minutes. Participants were instructed to remain stationary (no talking, laughing, deep breathing, sleeping, or swallowing) for approximately 10 seconds during the ECG recording. When an ECG was recorded at a time near that of a blood collection, the ECG was obtained prior to the blood collection. ECGs on Day 1 were recorded after initiation of the continuous subcutaneous infusion (CSCI) of ABBV-951 prior to the end of the study visit.

Outcome measures

Measure	ABBV-951 Low Dose Subgroup n=131 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was \< 2530 mg of Foslevodopa/day were analyzed as the Low Dose Subgroup.	ABBV-951 High Dose Subgroup n=113 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was ≥ 2530 mg of Foslevodopa/day were analyzed as the High Dose Subgroup.	ABBV-951 All Participants n=244 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period.
Electrocardiogram (ECG) Aggregate QRS Duration: Change From Baseline to End of Study Day 1 (postdose)	-2.3 milliseconds Standard Deviation 7.32	-0.8 milliseconds Standard Deviation 8.41	-1.6 milliseconds Standard Deviation 7.87
Electrocardiogram (ECG) Aggregate QRS Duration: Change From Baseline to End of Study Week 6	-0.5 milliseconds Standard Deviation 8.32	1.6 milliseconds Standard Deviation 8.96	0.5 milliseconds Standard Deviation 8.67
Electrocardiogram (ECG) Aggregate QRS Duration: Change From Baseline to End of Study Week 52	-0.2 milliseconds Standard Deviation 6.85	0.9 milliseconds Standard Deviation 7.29	0.3 milliseconds Standard Deviation 7.04

PRIMARY outcome

Timeframe: Baseline, Day 1 (postdose), Weeks 6 and 52

Population: Safety Analysis Set: all participants who received any ABBV-951 infusion with available data

12-lead electrocardiograms (ECGs) were recorded at study visits after the participant had been supine for at least 5 minutes. Participants were instructed to remain stationary (no talking, laughing, deep breathing, sleeping, or swallowing) for approximately 10 seconds during the ECG recording. When an ECG was recorded at a time near that of a blood collection, the ECG was obtained prior to the blood collection. ECGs on Day 1 were recorded after initiation of the continuous subcutaneous infusion (CSCI) of ABBV-951 prior to the end of the study visit.

Outcome measures

Measure	ABBV-951 Low Dose Subgroup n=131 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was \< 2530 mg of Foslevodopa/day were analyzed as the Low Dose Subgroup.	ABBV-951 High Dose Subgroup n=113 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was ≥ 2530 mg of Foslevodopa/day were analyzed as the High Dose Subgroup.	ABBV-951 All Participants n=244 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period.
Electrocardiogram (ECG) Aggregate QT Interval: Change From Baseline to End of Study Day 1 (postdose)	-5.3 milliseconds Standard Deviation 20.72	-4.2 milliseconds Standard Deviation 23.99	-4.8 milliseconds Standard Deviation 22.27
Electrocardiogram (ECG) Aggregate QT Interval: Change From Baseline to End of Study Week 6	6.4 milliseconds Standard Deviation 20.96	6.4 milliseconds Standard Deviation 24.61	6.4 milliseconds Standard Deviation 22.69
Electrocardiogram (ECG) Aggregate QT Interval: Change From Baseline to End of Study Week 52	9.8 milliseconds Standard Deviation 24.66	4.3 milliseconds Standard Deviation 26.24	7.3 milliseconds Standard Deviation 25.42

PRIMARY outcome

Timeframe: Baseline, Day 1 (postdose), Weeks 6 and 52

Population: Safety Analysis Set: all participants who received any ABBV-951 infusion with available data

12-lead electrocardiograms (ECGs) were recorded at study visits after the participant had been supine for at least 5 minutes. Participants were instructed to remain stationary (no talking, laughing, deep breathing, sleeping, or swallowing) for approximately 10 seconds during the ECG recording. When an ECG was recorded at a time near that of a blood collection, the ECG was obtained prior to the blood collection. ECGs on Day 1 were recorded after initiation of the continuous subcutaneous infusion (CSCI) of ABBV-951 prior to the end of the study visit.

Outcome measures

Measure	ABBV-951 Low Dose Subgroup n=131 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was \< 2530 mg of Foslevodopa/day were analyzed as the Low Dose Subgroup.	ABBV-951 High Dose Subgroup n=113 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was ≥ 2530 mg of Foslevodopa/day were analyzed as the High Dose Subgroup.	ABBV-951 All Participants n=244 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period.
Electrocardiogram (ECG) Aggregate QTcB Interval: Change From Baseline to End of Study Day 1 (postdose)	1.2 milliseconds Standard Deviation 17.96	2.0 milliseconds Standard Deviation 17.21	1.6 milliseconds Standard Deviation 17.58
Electrocardiogram (ECG) Aggregate QTcB Interval: Change From Baseline to End of Study Week 6	1.0 milliseconds Standard Deviation 19.91	0.6 milliseconds Standard Deviation 18.34	0.8 milliseconds Standard Deviation 19.14
Electrocardiogram (ECG) Aggregate QTcB Interval: Change From Baseline to End of Study Week 52	-0.1 milliseconds Standard Deviation 20.84	2.1 milliseconds Standard Deviation 18.33	0.9 milliseconds Standard Deviation 19.72

PRIMARY outcome

Timeframe: Baseline, Day 1 (postdose), Weeks 6 and 52

Population: Safety Analysis Set: all participants who received any ABBV-951 infusion with available data

12-lead electrocardiograms (ECGs) were recorded at study visits after the participant had been supine for at least 5 minutes. Participants were instructed to remain stationary (no talking, laughing, deep breathing, sleeping, or swallowing) for approximately 10 seconds during the ECG recording. When an ECG was recorded at a time near that of a blood collection, the ECG was obtained prior to the blood collection. ECGs on Day 1 were recorded after initiation of the continuous subcutaneous infusion (CSCI) of ABBV-951 prior to the end of the study visit.

Outcome measures

Measure	ABBV-951 Low Dose Subgroup n=131 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was \< 2530 mg of Foslevodopa/day were analyzed as the Low Dose Subgroup.	ABBV-951 High Dose Subgroup n=113 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was ≥ 2530 mg of Foslevodopa/day were analyzed as the High Dose Subgroup.	ABBV-951 All Participants n=244 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period.
Electrocardiogram (ECG) Aggregate QTcF Interval: Change From Baseline to End of Study Day 1 (postdose)	-1.0 milliseconds Standard Deviation 14.03	-0.2 milliseconds Standard Deviation 15.75	-0.6 milliseconds Standard Deviation 14.84
Electrocardiogram (ECG) Aggregate QTcF Interval: Change From Baseline to End of Study Week 6	3.1 milliseconds Standard Deviation 16.49	2.6 milliseconds Standard Deviation 15.63	2.9 milliseconds Standard Deviation 16.05
Electrocardiogram (ECG) Aggregate QTcF Interval: Change From Baseline to End of Study Week 52	3.4 milliseconds Standard Deviation 18.05	2.9 milliseconds Standard Deviation 15.40	3.2 milliseconds Standard Deviation 16.86

PRIMARY outcome

Timeframe: Baseline, Day 1 (postdose), Weeks 6 and 52

Population: Safety Analysis Set: all participants who received any ABBV-951 infusion with available data

12-lead electrocardiograms (ECGs) were recorded at study visits after the participant had been supine for at least 5 minutes. Participants were instructed to remain stationary (no talking, laughing, deep breathing, sleeping, or swallowing) for approximately 10 seconds during the ECG recording. When an ECG was recorded at a time near that of a blood collection, the ECG was obtained prior to the blood collection. ECGs on Day 1 were recorded after initiation of the continuous subcutaneous infusion (CSCI) of ABBV-951 prior to the end of the study visit.

Outcome measures

Measure	ABBV-951 Low Dose Subgroup n=131 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was \< 2530 mg of Foslevodopa/day were analyzed as the Low Dose Subgroup.	ABBV-951 High Dose Subgroup n=113 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was ≥ 2530 mg of Foslevodopa/day were analyzed as the High Dose Subgroup.	ABBV-951 All Participants n=244 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period.
Electrocardiogram (ECG) Aggregate RR Interval: Change From Baseline to End of Study Day 1 (postdose)	-30.7 milliseconds Standard Deviation 122.48	-28.3 milliseconds Standard Deviation 113.02	-29.6 milliseconds Standard Deviation 117.90
Electrocardiogram (ECG) Aggregate RR Interval: Change From Baseline to End of Study Week 6	22.6 milliseconds Standard Deviation 112.51	26.1 milliseconds Standard Deviation 129.35	24.2 milliseconds Standard Deviation 120.37
Electrocardiogram (ECG) Aggregate RR Interval: Change From Baseline to End of Study Week 52	41.8 milliseconds Standard Deviation 122.96	9.4 milliseconds Standard Deviation 141.91	27.5 milliseconds Standard Deviation 132.15

SECONDARY outcome

Timeframe: Baseline, Weeks 1, 6, 13, 26, 39, and 52

Population: Full Analysis Set: all participants who received any ABBV-951 infusion and had a Baseline and treatment observation for at least 1 efficacy outcome measure

Upon awakening and every 30 minutes during their normal waking time, participants recorded their state in the Parkinson's Disease Diary (PD Diary) for 2 consecutive days prior to study visits.

"Off" time is defined as periods of poor mobility, tremor, slowness, and stiffness. The daily "On" and "Off" times were normalized to a typical waking day (16 hours) to account for different sleep patterns across participants. When "Off" was the first morning symptom upon awakening, this was considered morning akinesia in this study.

Baseline value is defined as the average of normalized "Off" time collected over the 2 PD Diary days before the Enrollment visit. Negative changes from Baseline indicate improvement.

Outcome measures

Measure	ABBV-951 Low Dose Subgroup n=126 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was \< 2530 mg of Foslevodopa/day were analyzed as the Low Dose Subgroup.	ABBV-951 High Dose Subgroup n=110 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was ≥ 2530 mg of Foslevodopa/day were analyzed as the High Dose Subgroup.	ABBV-951 All Participants n=236 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period.
Average Daily Normalized "Off" Time: Change From Baseline to End of Study Week 1	-2.04 hours Standard Deviation 3.51	-1.84 hours Standard Deviation 3.88	-1.95 hours Standard Deviation 3.68
Average Daily Normalized "Off" Time: Change From Baseline to End of Study Week 6	-2.43 hours Standard Deviation 3.66	-2.36 hours Standard Deviation 3.56	-2.40 hours Standard Deviation 3.61
Average Daily Normalized "Off" Time: Change From Baseline to End of Study Week 13	-2.50 hours Standard Deviation 3.83	-2.34 hours Standard Deviation 3.57	-2.43 hours Standard Deviation 3.70
Average Daily Normalized "Off" Time: Change From Baseline to End of Study Week 26	-3.31 hours Standard Deviation 3.36	-3.38 hours Standard Deviation 3.15	-3.35 hours Standard Deviation 3.25
Average Daily Normalized "Off" Time: Change From Baseline to End of Study Week 39	-3.25 hours Standard Deviation 3.43	-3.52 hours Standard Deviation 2.92	-3.37 hours Standard Deviation 3.21
Average Daily Normalized "Off" Time: Change From Baseline to End of Study Week 52	-3.43 hours Standard Deviation 3.16	-3.59 hours Standard Deviation 3.11	-3.51 hours Standard Deviation 3.12

SECONDARY outcome

Timeframe: Baseline, Weeks 1, 6, 13, 26, 39, and 52

Population: Full Analysis Set: all participants who received any ABBV-951 infusion and had a Baseline and treatment observation for at least 1 efficacy outcome measure

Upon awakening and every 30 minutes during their normal waking time, participants recorded their state in the Parkinson's Disease Diary (PD Diary) for 2 consecutive days prior to study visits.

"On" time is defined as periods of good motor symptom control. The daily "On" and "Off" times were normalized to a typical waking day (16 hours) to account for different sleep patterns across participants.

Baseline value is defined as the average of normalized "On" time with troublesome dyskinesia collected over the 2 PD Diary days before the Enrollment visit. Negative changes from Baseline indicate improvement.

Outcome measures

Measure	ABBV-951 Low Dose Subgroup n=126 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was \< 2530 mg of Foslevodopa/day were analyzed as the Low Dose Subgroup.	ABBV-951 High Dose Subgroup n=110 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was ≥ 2530 mg of Foslevodopa/day were analyzed as the High Dose Subgroup.	ABBV-951 All Participants n=236 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period.
Average Daily Normalized "On" Time With Troublesome Dyskinesia: Change From Baseline to End of Study Week 1	-0.00 hours Standard Deviation 2.10	0.11 hours Standard Deviation 1.64	0.05 hours Standard Deviation 1.89
Average Daily Normalized "On" Time With Troublesome Dyskinesia: Change From Baseline to End of Study Week 6	-0.56 hours Standard Deviation 1.95	-0.23 hours Standard Deviation 1.05	-0.41 hours Standard Deviation 1.60
Average Daily Normalized "On" Time With Troublesome Dyskinesia: Change From Baseline to End of Study Week 13	-0.60 hours Standard Deviation 1.72	-0.38 hours Standard Deviation 1.04	-0.50 hours Standard Deviation 1.45
Average Daily Normalized "On" Time With Troublesome Dyskinesia: Change From Baseline to End of Study Week 26	-0.61 hours Standard Deviation 1.95	-0.27 hours Standard Deviation 1.73	-0.45 hours Standard Deviation 1.85
Average Daily Normalized "On" Time With Troublesome Dyskinesia: Change From Baseline to End of Study Week 39	-0.49 hours Standard Deviation 1.07	-0.17 hours Standard Deviation 1.59	-0.35 hours Standard Deviation 1.33
Average Daily Normalized "On" Time With Troublesome Dyskinesia: Change From Baseline to End of Study Week 52	-0.64 hours Standard Deviation 1.73	0.17 hours Standard Deviation 2.53	-0.27 hours Standard Deviation 2.16

SECONDARY outcome

Timeframe: Baseline, Weeks 1, 6, 13, 26, 39, and 52

Population: Full Analysis Set: all participants who received any ABBV-951 infusion and had a Baseline and treatment observation for at least 1 efficacy outcome measure

Upon awakening and every 30 minutes during their normal waking time, participants recorded their state in the Parkinson's Disease Diary (PD Diary) for 2 consecutive days prior to study visits.

"On" time is defined as periods of good motor symptom control. The daily "On" and "Off" times were normalized to a typical waking day (16 hours) to account for different sleep patterns across participants.

Baseline value is defined as the average of normalized "On" time without troublesome dyskinesia collected over the 2 PD Diary days before the Enrollment visit. Positive changes from Baseline indicate improvement.

Outcome measures

Measure	ABBV-951 Low Dose Subgroup n=126 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was \< 2530 mg of Foslevodopa/day were analyzed as the Low Dose Subgroup.	ABBV-951 High Dose Subgroup n=110 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was ≥ 2530 mg of Foslevodopa/day were analyzed as the High Dose Subgroup.	ABBV-951 All Participants n=236 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period.
Average Daily Normalized "On" Time Without Troublesome Dyskinesia: Change From Baseline to End of Study Week 1	2.04 hours Standard Deviation 3.55	1.74 hours Standard Deviation 4.04	1.90 hours Standard Deviation 3.78
Average Daily Normalized "On" Time Without Troublesome Dyskinesia: Change From Baseline to End of Study Week 6	2.99 hours Standard Deviation 3.60	2.60 hours Standard Deviation 3.58	2.81 hours Standard Deviation 3.59
Average Daily Normalized "On" Time Without Troublesome Dyskinesia: Change From Baseline to End of Study Week 13	3.10 hours Standard Deviation 3.32	2.72 hours Standard Deviation 3.68	2.93 hours Standard Deviation 3.48
Average Daily Normalized "On" Time Without Troublesome Dyskinesia: Change From Baseline to End of Study Week 26	3.92 hours Standard Deviation 3.76	3.65 hours Standard Deviation 3.31	3.79 hours Standard Deviation 3.55
Average Daily Normalized "On" Time Without Troublesome Dyskinesia: Change From Baseline to End of Study Week 39	3.74 hours Standard Deviation 3.40	3.69 hours Standard Deviation 3.32	3.71 hours Standard Deviation 3.35
Average Daily Normalized "On" Time Without Troublesome Dyskinesia: Change From Baseline to End of Study Week 52	4.08 hours Standard Deviation 3.28	3.43 hours Standard Deviation 3.28	3.77 hours Standard Deviation 3.28

SECONDARY outcome

Timeframe: Baseline, Day 2, Weeks 1, 2, 3, 4, 6, 13, 26, 39, and 52

Population: Full Analysis Set: all participants who received any ABBV-951 infusion and had a Baseline and treatment observation for at least 1 efficacy outcome measure

The Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) is an investigator-used rating tool to follow the longitudinal course of Parkinson's Disease (PD). Part I assesses the participant's non-motor aspects of experiences of daily living (nM-EDL) with 13 questions. (The numeric score for each question is between 0-4; 0=Normal,1=Slight,2=Mild,3=Moderate,4=Severe). Part I scores range from 0 to 52, with higher scores indicating more severe symptoms of PD. Negative changes from Baseline indicate improvement.

Outcome measures

Measure	ABBV-951 Low Dose Subgroup n=131 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was \< 2530 mg of Foslevodopa/day were analyzed as the Low Dose Subgroup.	ABBV-951 High Dose Subgroup n=113 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was ≥ 2530 mg of Foslevodopa/day were analyzed as the High Dose Subgroup.	ABBV-951 All Participants n=244 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period.
Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part I Score: Change From Baseline to End of Study Day 2	-2.6 units on a scale Standard Deviation 4.28	-1.8 units on a scale Standard Deviation 3.61	-2.3 units on a scale Standard Deviation 4.00
Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part I Score: Change From Baseline to End of Study Week 1	-2.6 units on a scale Standard Deviation 5.84	-3.3 units on a scale Standard Deviation 5.50	-2.9 units on a scale Standard Deviation 5.68
Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part I Score: Change From Baseline to End of Study Week 2	-2.5 units on a scale Standard Deviation 5.29	-2.1 units on a scale Standard Deviation 5.10	-2.3 units on a scale Standard Deviation 5.20
Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part I Score: Change From Baseline to End of Study Week 3	-2.3 units on a scale Standard Deviation 5.65	-2.9 units on a scale Standard Deviation 5.91	-2.6 units on a scale Standard Deviation 5.77
Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part I Score: Change From Baseline to End of Study Week 4	-1.7 units on a scale Standard Deviation 6.22	-3.0 units on a scale Standard Deviation 5.42	-2.3 units on a scale Standard Deviation 5.88
Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part I Score: Change From Baseline to End of Study Week 6	-1.1 units on a scale Standard Deviation 7.00	-1.7 units on a scale Standard Deviation 5.15	-1.4 units on a scale Standard Deviation 6.21
Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part I Score: Change From Baseline to End of Study Week 13	-1.8 units on a scale Standard Deviation 5.80	-1.7 units on a scale Standard Deviation 5.59	-1.7 units on a scale Standard Deviation 5.69
Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part I Score: Change From Baseline to End of Study Week 26	-1.1 units on a scale Standard Deviation 5.01	-0.7 units on a scale Standard Deviation 5.88	-0.9 units on a scale Standard Deviation 5.42
Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part I Score: Change From Baseline to End of Study Week 39	-0.7 units on a scale Standard Deviation 5.64	0.1 units on a scale Standard Deviation 6.00	-0.4 units on a scale Standard Deviation 5.80
Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part I Score: Change From Baseline to End of Study Week 52	-0.5 units on a scale Standard Deviation 5.30	-1.3 units on a scale Standard Deviation 6.22	-0.9 units on a scale Standard Deviation 5.71

SECONDARY outcome

Timeframe: Baseline, Day 2, Weeks 1, 2, 3, 4, 6, 13, 26, 39, and 52

Population: Full Analysis Set: all participants who received any ABBV-951 infusion and had a Baseline and treatment observation for at least 1 efficacy outcome measure

The Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) is an investigator-used rating tool to follow the longitudinal course of Parkinson's Disease (PD). Part II assesses the participant's motor experiences of daily living (M-EDL) with 13 questions. (The numeric score for each question is between 0-4; 0=Normal,1=Slight,2=Mild,3=Moderate,4=Severe). Part II scores range from 0 to 52, with higher scores indicating more severe symptoms of PD. Negative changes from Baseline indicate improvement.

Outcome measures

Measure	ABBV-951 Low Dose Subgroup n=131 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was \< 2530 mg of Foslevodopa/day were analyzed as the Low Dose Subgroup.	ABBV-951 High Dose Subgroup n=113 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was ≥ 2530 mg of Foslevodopa/day were analyzed as the High Dose Subgroup.	ABBV-951 All Participants n=244 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period.
Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part II Score: Change From Baseline to End of Study Day 2	-2.8 units on a scale Standard Deviation 4.55	-1.2 units on a scale Standard Deviation 4.25	-2.1 units on a scale Standard Deviation 4.47
Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part II Score: Change From Baseline to End of Study Week 1	-3.6 units on a scale Standard Deviation 4.98	-3.9 units on a scale Standard Deviation 5.85	-3.7 units on a scale Standard Deviation 5.40
Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part II Score: Change From Baseline to End of Study Week 2	-3.3 units on a scale Standard Deviation 6.06	-3.4 units on a scale Standard Deviation 6.53	-3.3 units on a scale Standard Deviation 6.26
Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part II Score: Change From Baseline to End of Study Week 3	-3.5 units on a scale Standard Deviation 5.83	-3.9 units on a scale Standard Deviation 6.63	-3.7 units on a scale Standard Deviation 6.21
Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part II Score: Change From Baseline to End of Study Week 4	-2.6 units on a scale Standard Deviation 5.50	-4.9 units on a scale Standard Deviation 6.32	-3.7 units on a scale Standard Deviation 5.98
Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part II Score: Change From Baseline to End of Study Week 6	-2.5 units on a scale Standard Deviation 6.60	-4.2 units on a scale Standard Deviation 6.09	-3.3 units on a scale Standard Deviation 6.41
Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part II Score: Change From Baseline to End of Study Week 13	-3.2 units on a scale Standard Deviation 6.44	-4.3 units on a scale Standard Deviation 6.57	-3.7 units on a scale Standard Deviation 6.50
Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part II Score: Change From Baseline to End of Study Week 26	-2.6 units on a scale Standard Deviation 6.27	-3.9 units on a scale Standard Deviation 7.05	-3.2 units on a scale Standard Deviation 6.65
Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part II Score: Change From Baseline to End of Study Week 39	-2.6 units on a scale Standard Deviation 6.32	-4.0 units on a scale Standard Deviation 6.93	-3.2 units on a scale Standard Deviation 6.61
Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part II Score: Change From Baseline to End of Study Week 52	-2.1 units on a scale Standard Deviation 6.94	-4.5 units on a scale Standard Deviation 7.07	-3.2 units on a scale Standard Deviation 7.07

SECONDARY outcome

Timeframe: Baseline, Day 2, Weeks 1, 2, 3, 4, 6, 13, 26, 39, and 52

Population: Full Analysis Set: all participants who received any ABBV-951 infusion and had a Baseline and treatment observation for at least 1 efficacy outcome measure

The Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) is an investigator-used rating tool to follow the longitudinal course of Parkinson's Disease (PD). Part III assesses the participant's motor examination (including Hoehn and Yahr stage) with 33 questions. (The numeric score for each question is between 0-4; 0=Normal,1=Slight,2=Mild,3=Moderate,4=Severe). Part III scores range from 0 to 132, with higher scores indicating more severe symptoms of PD. Negative changes from Baseline indicate improvement.

Outcome measures

Measure	ABBV-951 Low Dose Subgroup n=131 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was \< 2530 mg of Foslevodopa/day were analyzed as the Low Dose Subgroup.	ABBV-951 High Dose Subgroup n=113 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was ≥ 2530 mg of Foslevodopa/day were analyzed as the High Dose Subgroup.	ABBV-951 All Participants n=244 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period.
Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III Score: Change From Baseline to End of Study Day 2	-0.6 units on a scale Standard Deviation 8.45	-0.8 units on a scale Standard Deviation 9.20	-0.7 units on a scale Standard Deviation 8.78
Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III Score: Change From Baseline to End of Study Week 1	2.0 units on a scale Standard Deviation 11.55	3.8 units on a scale Standard Deviation 11.00	2.8 units on a scale Standard Deviation 11.31
Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III Score: Change From Baseline to End of Study Week 2	4.1 units on a scale Standard Deviation 13.02	1.4 units on a scale Standard Deviation 10.93	2.9 units on a scale Standard Deviation 12.18
Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III Score: Change From Baseline to End of Study Week 3	3.9 units on a scale Standard Deviation 11.98	2.2 units on a scale Standard Deviation 12.07	3.1 units on a scale Standard Deviation 12.02
Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III Score: Change From Baseline to End of Study Week 4	2.7 units on a scale Standard Deviation 12.84	0.0 units on a scale Standard Deviation 10.97	1.5 units on a scale Standard Deviation 12.05
Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III Score: Change From Baseline to End of Study Week 6	2.4 units on a scale Standard Deviation 13.74	-0.7 units on a scale Standard Deviation 9.58	0.9 units on a scale Standard Deviation 12.07
Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III Score: Change From Baseline to End of Study Week 13	1.4 units on a scale Standard Deviation 13.79	-1.6 units on a scale Standard Deviation 11.82	0.1 units on a scale Standard Deviation 13.01
Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III Score: Change From Baseline to End of Study Week 26	1.4 units on a scale Standard Deviation 12.71	0.1 units on a scale Standard Deviation 11.61	0.8 units on a scale Standard Deviation 12.19
Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III Score: Change From Baseline to End of Study Week 39	1.9 units on a scale Standard Deviation 12.70	2.3 units on a scale Standard Deviation 13.26	2.1 units on a scale Standard Deviation 12.89
Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III Score: Change From Baseline to End of Study Week 52	1.8 units on a scale Standard Deviation 12.53	1.7 units on a scale Standard Deviation 13.02	1.7 units on a scale Standard Deviation 12.69

SECONDARY outcome

Timeframe: Baseline, Day 2, Weeks 1, 2, 3, 4, 6, 13, 26, 39, and 52

Population: Full Analysis Set: all participants who received any ABBV-951 infusion and had a Baseline and treatment observation for at least 1 efficacy outcome measure

The Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) is an investigator-used rating tool to follow the longitudinal course of Parkinson's Disease (PD). Part IV assesses the participant's motor complications with 6 questions. (The numeric score for each question is between 0-4; 0=Normal,1=Slight,2=Mild,3=Moderate,4=Severe). Part IV scores range from 0 to 24, with higher scores indicating more severe symptoms of PD. Negative changes from Baseline indicate improvement.

Outcome measures

Measure	ABBV-951 Low Dose Subgroup n=131 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was \< 2530 mg of Foslevodopa/day were analyzed as the Low Dose Subgroup.	ABBV-951 High Dose Subgroup n=113 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was ≥ 2530 mg of Foslevodopa/day were analyzed as the High Dose Subgroup.	ABBV-951 All Participants n=244 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period.
Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part IV Score: Change From Baseline to End of Study Week 52	-4.1 units on a scale Standard Deviation 3.75	-3.8 units on a scale Standard Deviation 4.71	-3.9 units on a scale Standard Deviation 4.19
Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part IV Score: Change From Baseline to End of Study Day 2	-1.8 units on a scale Standard Deviation 3.57	-1.1 units on a scale Standard Deviation 3.45	-1.5 units on a scale Standard Deviation 3.52
Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part IV Score: Change From Baseline to End of Study Week 1	-1.7 units on a scale Standard Deviation 3.86	-1.7 units on a scale Standard Deviation 4.10	-1.7 units on a scale Standard Deviation 3.96
Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part IV Score: Change From Baseline to End of Study Week 2	-2.5 units on a scale Standard Deviation 3.58	-2.3 units on a scale Standard Deviation 3.56	-2.4 units on a scale Standard Deviation 3.57
Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part IV Score: Change From Baseline to End of Study Week 3	-2.1 units on a scale Standard Deviation 4.06	-2.3 units on a scale Standard Deviation 3.74	-2.2 units on a scale Standard Deviation 3.90
Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part IV Score: Change From Baseline to End of Study Week 4	-3.0 units on a scale Standard Deviation 3.69	-2.6 units on a scale Standard Deviation 3.78	-2.8 units on a scale Standard Deviation 3.73
Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part IV Score: Change From Baseline to End of Study Week 6	-2.6 units on a scale Standard Deviation 3.34	-2.8 units on a scale Standard Deviation 3.90	-2.7 units on a scale Standard Deviation 3.61
Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part IV Score: Change From Baseline to End of Study Week 13	-3.7 units on a scale Standard Deviation 3.47	-3.3 units on a scale Standard Deviation 4.04	-3.5 units on a scale Standard Deviation 3.74
Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part IV Score: Change From Baseline to End of Study Week 26	-3.5 units on a scale Standard Deviation 3.43	-3.5 units on a scale Standard Deviation 4.12	-3.5 units on a scale Standard Deviation 3.76
Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part IV Score: Change From Baseline to End of Study Week 39	-3.5 units on a scale Standard Deviation 4.06	-3.5 units on a scale Standard Deviation 4.11	-3.5 units on a scale Standard Deviation 4.07

SECONDARY outcome

Timeframe: Baseline, Weeks 6, 13, 26, 39, and 52

Population: Full Analysis Set: all participants who received any ABBV-951 infusion and had a Baseline and treatment observation for at least 1 efficacy outcome measure

The PDSS-2 consists of 15 questions that evaluate motor and non-motor symptoms at night and upon wakening, as well as disturbed sleep grouped into 3 domains: motor symptoms at night (5 items), Parkinson's Disease (PD) symptoms at night (5 items), and disturbed sleep (5 items). The frequency is assessed for the 15 sleep problems based on a 5-point Likert-type scale (ranging from 0 [never] to 4 [very often] with the exception of Question 1 score ranging from 0 [very often] to 4 [never]). Scores are calculated for each of the 3 domains as well as a total score. The PDSS-2 domain scores range from 0 to 20 and the total score is a sum of the 3 domains and ranges from 0 to 60. Higher scores indicate higher frequency and more severe impact of PD on sleep. Negative changes indicate improvement from Baseline.

Outcome measures

Measure	ABBV-951 Low Dose Subgroup n=131 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was \< 2530 mg of Foslevodopa/day were analyzed as the Low Dose Subgroup.	ABBV-951 High Dose Subgroup n=112 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was ≥ 2530 mg of Foslevodopa/day were analyzed as the High Dose Subgroup.	ABBV-951 All Participants n=243 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period.
Sleep Symptoms as Assessed by the Parkinson's Disease Sleep Scale-2 (PDSS-2) Total Score: Change From Baseline to End of Study Week 6	-5.0 units on a scale Standard Deviation 11.39	-7.3 units on a scale Standard Deviation 8.81	-6.1 units on a scale Standard Deviation 10.31
Sleep Symptoms as Assessed by the Parkinson's Disease Sleep Scale-2 (PDSS-2) Total Score: Change From Baseline to End of Study Week 13	-6.9 units on a scale Standard Deviation 10.76	-8.2 units on a scale Standard Deviation 8.89	-7.5 units on a scale Standard Deviation 9.94
Sleep Symptoms as Assessed by the Parkinson's Disease Sleep Scale-2 (PDSS-2) Total Score: Change From Baseline to End of Study Week 26	-5.0 units on a scale Standard Deviation 13.06	-8.4 units on a scale Standard Deviation 8.07	-6.6 units on a scale Standard Deviation 11.12
Sleep Symptoms as Assessed by the Parkinson's Disease Sleep Scale-2 (PDSS-2) Total Score: Change From Baseline to End of Study Week 39	-7.0 units on a scale Standard Deviation 11.19	-7.2 units on a scale Standard Deviation 9.21	-7.1 units on a scale Standard Deviation 10.32
Sleep Symptoms as Assessed by the Parkinson's Disease Sleep Scale-2 (PDSS-2) Total Score: Change From Baseline to End of Study Week 52	-6.5 units on a scale Standard Deviation 12.34	-8.7 units on a scale Standard Deviation 8.19	-7.5 units on a scale Standard Deviation 10.75

SECONDARY outcome

Timeframe: Baseline, Weeks 6, 13, 26, 39, and 52

Population: Full Analysis Set: all participants who received any ABBV-951 infusion and had a Baseline and treatment observation for at least 1 efficacy outcome measure

The Parkinson's Disease Questionnaire (PDQ-39) is a disease-specific instrument designed to measure aspects of health that are relevant to participants with Parkinson's Disease (PD), and which may not be included in general health status questionnaires. Each item is scored on the following 5-point scale: 0 = never, 1 = occasionally, 2 = sometimes, 3 = often, 4 = always (or cannot do at all, if applicable). Higher scores are consistently associated with more severe symptoms of the disease such as tremors and stiffness. The results can be presented in either domain scores or as a summary index score. The full range of the PDQ-39 summary index score is from 0 (no patient-related symptoms/quality of life unaffected) to 100 (highest patient-related symptoms/low quality of life). Negative changes indicate improvement from Baseline.

Outcome measures

Measure	ABBV-951 Low Dose Subgroup n=131 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was \< 2530 mg of Foslevodopa/day were analyzed as the Low Dose Subgroup.	ABBV-951 High Dose Subgroup n=112 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was ≥ 2530 mg of Foslevodopa/day were analyzed as the High Dose Subgroup.	ABBV-951 All Participants n=243 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period.
Quality of Life Assessed by the Parkinson's Disease Questionnaire-39 Items (PDQ-39) Summary Index Score: Change From Baseline to End of Study Week 6	-7.0 units on a scale Standard Deviation 14.53	-8.4 units on a scale Standard Deviation 10.53	-7.6 units on a scale Standard Deviation 12.81
Quality of Life Assessed by the Parkinson's Disease Questionnaire-39 Items (PDQ-39) Summary Index Score: Change From Baseline to End of Study Week 13	-8.3 units on a scale Standard Deviation 15.33	-8.2 units on a scale Standard Deviation 11.18	-8.3 units on a scale Standard Deviation 13.57
Quality of Life Assessed by the Parkinson's Disease Questionnaire-39 Items (PDQ-39) Summary Index Score: Change From Baseline to End of Study Week 26	-7.4 units on a scale Standard Deviation 13.00	-7.1 units on a scale Standard Deviation 12.27	-7.3 units on a scale Standard Deviation 12.62
Quality of Life Assessed by the Parkinson's Disease Questionnaire-39 Items (PDQ-39) Summary Index Score: Change From Baseline to End of Study Week 39	-7.8 units on a scale Standard Deviation 13.81	-7.5 units on a scale Standard Deviation 13.58	-7.7 units on a scale Standard Deviation 13.66
Quality of Life Assessed by the Parkinson's Disease Questionnaire-39 Items (PDQ-39) Summary Index Score: Change From Baseline to End of Study Week 52	-7.2 units on a scale Standard Deviation 14.65	-7.2 units on a scale Standard Deviation 12.35	-7.2 units on a scale Standard Deviation 13.65

SECONDARY outcome

Timeframe: Baseline, Weeks 6, 13, 26, 39, and 52

Population: Full Analysis Set: all participants who received any ABBV-951 infusion and had a Baseline and treatment observation for at least 1 efficacy outcome measure

The EuroQol 5-dimension questionnaire (EQ-5D-5L) is a standardized non-disease specific instrument for describing and valuing health-related quality of life. The EQ-5D-5L descriptive system comprises 5 dimensions of health (mobility, self -care, usual activities, pain/discomfort, and anxiety/depression) to describe the participant's current health state. Each dimension comprises 5 levels with corresponding numeric scores, where 1 indicates no problems, and 5 indicates extreme problems. The health status is converted to an index value using the country-specific weighted scoring algorithm for the United States (US). The summary index value for the US ranges from a worst score of -0.109 to a best score of 1. An increase in the EQ-5D-5L total score indicates improvement.

Outcome measures

Measure	ABBV-951 Low Dose Subgroup n=125 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was \< 2530 mg of Foslevodopa/day were analyzed as the Low Dose Subgroup.	ABBV-951 High Dose Subgroup n=104 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was ≥ 2530 mg of Foslevodopa/day were analyzed as the High Dose Subgroup.	ABBV-951 All Participants n=229 Participants After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period.
The EuroQol 5-Dimension Questionnaire (EQ-5D-5L) Quality of Life Summary Index: Change From Baseline to End of Study Week 6	0.060 units on a scale Standard Deviation 0.1921	0.113 units on a scale Standard Deviation 0.1780	0.085 units on a scale Standard Deviation 0.1870
The EuroQol 5-Dimension Questionnaire (EQ-5D-5L) Quality of Life Summary Index: Change From Baseline to End of Study Week 13	0.064 units on a scale Standard Deviation 0.2153	0.122 units on a scale Standard Deviation 0.1984	0.090 units on a scale Standard Deviation 0.2092
The EuroQol 5-Dimension Questionnaire (EQ-5D-5L) Quality of Life Summary Index: Change From Baseline to End of Study Week 26	0.074 units on a scale Standard Deviation 0.1771	0.122 units on a scale Standard Deviation 0.1803	0.096 units on a scale Standard Deviation 0.1795
The EuroQol 5-Dimension Questionnaire (EQ-5D-5L) Quality of Life Summary Index: Change From Baseline to End of Study Week 39	0.075 units on a scale Standard Deviation 0.1842	0.129 units on a scale Standard Deviation 0.1995	0.097 units on a scale Standard Deviation 0.1916
The EuroQol 5-Dimension Questionnaire (EQ-5D-5L) Quality of Life Summary Index: Change From Baseline to End of Study Week 52	0.076 units on a scale Standard Deviation 0.2062	0.126 units on a scale Standard Deviation 0.2213	0.097 units on a scale Standard Deviation 0.2134

Adverse Events

ABBV-951 Low Dose Subgroup

Serious events: 32 serious events

Other events: 111 other events

Deaths: 0 deaths

ABBV-951 High Dose Subgroup

Serious events: 31 serious events

Other events: 107 other events

Deaths: 5 deaths

ABBV-951 All Participants

Serious events: 63 serious events

Other events: 218 other events

Deaths: 5 deaths

Serious adverse events

Measure	ABBV-951 Low Dose Subgroup n=131 participants at risk After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was \< 2530 mg of Foslevodopa/day were analyzed as the Low Dose Subgroup.	ABBV-951 High Dose Subgroup n=113 participants at risk After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was ≥ 2530 mg of Foslevodopa/day were analyzed as the High Dose Subgroup.	ABBV-951 All Participants n=244 participants at risk After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period.
Cardiac disorders ACUTE MYOCARDIAL INFARCTION	0.76% 1/131 • Number of events 1 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	0.00% 0/113 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	0.41% 1/244 • Number of events 1 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.
Cardiac disorders ATRIAL FIBRILLATION	0.00% 0/131 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	0.88% 1/113 • Number of events 1 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	0.41% 1/244 • Number of events 1 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.
Cardiac disorders CARDIAC ARREST	0.76% 1/131 • Number of events 1 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	0.00% 0/113 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	0.41% 1/244 • Number of events 1 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.
Cardiac disorders CARDIO-RESPIRATORY ARREST	0.00% 0/131 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	0.88% 1/113 • Number of events 1 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	0.41% 1/244 • Number of events 1 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.
Cardiac disorders CORONARY ARTERY DISEASE	0.76% 1/131 • Number of events 1 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	0.88% 1/113 • Number of events 1 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	0.82% 2/244 • Number of events 2 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.
Eye disorders PERIORBITAL PAIN	0.00% 0/131 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	0.88% 1/113 • Number of events 1 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	0.41% 1/244 • Number of events 1 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.
Eye disorders PERIORBITAL SWELLING	0.00% 0/131 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	0.88% 1/113 • Number of events 1 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	0.41% 1/244 • Number of events 1 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.
Gastrointestinal disorders COLITIS ISCHAEMIC	0.76% 1/131 • Number of events 1 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	0.00% 0/113 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	0.41% 1/244 • Number of events 1 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.
Gastrointestinal disorders INTESTINAL HAEMORRHAGE	0.76% 1/131 • Number of events 1 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	0.00% 0/113 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	0.41% 1/244 • Number of events 1 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.
General disorders ASTHENIA	0.76% 1/131 • Number of events 1 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	0.00% 0/113 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	0.41% 1/244 • Number of events 1 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.
General disorders CHEST DISCOMFORT	0.00% 0/131 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	0.88% 1/113 • Number of events 1 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	0.41% 1/244 • Number of events 1 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.
General disorders CHEST PAIN	0.76% 1/131 • Number of events 1 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	0.00% 0/113 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	0.41% 1/244 • Number of events 1 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.
General disorders HYPOTHERMIA	0.76% 1/131 • Number of events 1 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	0.00% 0/113 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	0.41% 1/244 • Number of events 1 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.
General disorders INFUSION SITE HAEMATOMA	0.00% 0/131 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	0.88% 1/113 • Number of events 1 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	0.41% 1/244 • Number of events 1 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.
General disorders INFUSION SITE INJURY	0.00% 0/131 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	0.88% 1/113 • Number of events 1 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	0.41% 1/244 • Number of events 1 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.
Infections and infestations ABSCESS LIMB	0.00% 0/131 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	0.88% 1/113 • Number of events 1 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	0.41% 1/244 • Number of events 1 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.
Infections and infestations COVID-19	0.76% 1/131 • Number of events 1 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	0.00% 0/113 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	0.41% 1/244 • Number of events 1 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.
Infections and infestations CELLULITIS	0.00% 0/131 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	0.88% 1/113 • Number of events 1 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	0.41% 1/244 • Number of events 1 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.
Infections and infestations INFUSION SITE ABSCESS	3.8% 5/131 • Number of events 5 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	2.7% 3/113 • Number of events 5 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	3.3% 8/244 • Number of events 10 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.
Infections and infestations INFUSION SITE CELLULITIS	3.1% 4/131 • Number of events 4 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	5.3% 6/113 • Number of events 6 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	4.1% 10/244 • Number of events 10 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.
Infections and infestations INFUSION SITE INFECTION	0.00% 0/131 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	0.88% 1/113 • Number of events 1 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	0.41% 1/244 • Number of events 1 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.
Infections and infestations PAROTID ABSCESS	0.00% 0/131 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	0.88% 1/113 • Number of events 1 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	0.41% 1/244 • Number of events 1 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.
Infections and infestations PNEUMONIA	1.5% 2/131 • Number of events 2 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	0.88% 1/113 • Number of events 2 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	1.2% 3/244 • Number of events 4 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.
Infections and infestations SEPSIS	2.3% 3/131 • Number of events 3 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	0.00% 0/113 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	1.2% 3/244 • Number of events 3 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.
Infections and infestations SEPTIC SHOCK	0.76% 1/131 • Number of events 1 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	0.00% 0/113 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	0.41% 1/244 • Number of events 1 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.
Infections and infestations URINARY TRACT INFECTION	1.5% 2/131 • Number of events 2 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	1.8% 2/113 • Number of events 2 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	1.6% 4/244 • Number of events 4 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.
Injury, poisoning and procedural complications FACE INJURY	0.00% 0/131 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	0.88% 1/113 • Number of events 1 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	0.41% 1/244 • Number of events 1 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.
Injury, poisoning and procedural complications FALL	0.76% 1/131 • Number of events 1 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	0.88% 1/113 • Number of events 1 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	0.82% 2/244 • Number of events 2 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.
Injury, poisoning and procedural complications SUBDURAL HAEMATOMA	0.00% 0/131 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	0.88% 1/113 • Number of events 1 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	0.41% 1/244 • Number of events 1 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.
Investigations BLOOD SODIUM DECREASED	0.76% 1/131 • Number of events 1 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	0.00% 0/113 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	0.41% 1/244 • Number of events 1 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.
Metabolism and nutrition disorders DEHYDRATION	0.76% 1/131 • Number of events 1 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	0.00% 0/113 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	0.41% 1/244 • Number of events 1 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.
Metabolism and nutrition disorders HYPOKALAEMIA	0.00% 0/131 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	0.88% 1/113 • Number of events 1 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	0.41% 1/244 • Number of events 1 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.
Metabolism and nutrition disorders HYPONATRAEMIA	0.76% 1/131 • Number of events 1 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	0.00% 0/113 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	0.41% 1/244 • Number of events 1 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.
Musculoskeletal and connective tissue disorders ARTHRITIS REACTIVE	0.76% 1/131 • Number of events 1 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	0.00% 0/113 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	0.41% 1/244 • Number of events 1 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.
Musculoskeletal and connective tissue disorders OSTEOARTHRITIS	0.00% 0/131 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	0.88% 1/113 • Number of events 1 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	0.41% 1/244 • Number of events 1 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.
Musculoskeletal and connective tissue disorders RHABDOMYOLYSIS	0.76% 1/131 • Number of events 1 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	0.00% 0/113 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	0.41% 1/244 • Number of events 1 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.
Musculoskeletal and connective tissue disorders SACROILIAC JOINT DYSFUNCTION	0.76% 1/131 • Number of events 1 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	0.00% 0/113 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	0.41% 1/244 • Number of events 1 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) RECTAL ADENOCARCINOMA	0.76% 1/131 • Number of events 1 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	0.00% 0/113 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	0.41% 1/244 • Number of events 1 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.
Nervous system disorders CEREBRAL MASS EFFECT	0.00% 0/131 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	0.88% 1/113 • Number of events 1 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	0.41% 1/244 • Number of events 1 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.
Nervous system disorders CEREBROVASCULAR ACCIDENT	0.00% 0/131 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	0.88% 1/113 • Number of events 1 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	0.41% 1/244 • Number of events 1 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.
Nervous system disorders COGNITIVE DISORDER	0.76% 1/131 • Number of events 1 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	0.88% 1/113 • Number of events 1 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	0.82% 2/244 • Number of events 2 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.
Nervous system disorders DIZZINESS	0.76% 1/131 • Number of events 1 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	0.00% 0/113 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	0.41% 1/244 • Number of events 1 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.
Nervous system disorders DYSARTHRIA	0.00% 0/131 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	0.88% 1/113 • Number of events 1 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	0.41% 1/244 • Number of events 1 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.
Nervous system disorders DYSTONIA	0.00% 0/131 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	1.8% 2/113 • Number of events 3 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	0.82% 2/244 • Number of events 3 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.
Nervous system disorders GENERALISED TONIC-CLONIC SEIZURE	0.00% 0/131 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	0.88% 1/113 • Number of events 1 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	0.41% 1/244 • Number of events 1 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.
Nervous system disorders HEMIANAESTHESIA	0.00% 0/131 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	0.88% 1/113 • Number of events 1 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	0.41% 1/244 • Number of events 1 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.
Nervous system disorders HEMIPARESIS	0.00% 0/131 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	0.88% 1/113 • Number of events 1 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	0.41% 1/244 • Number of events 1 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.
Nervous system disorders LOSS OF CONSCIOUSNESS	0.76% 1/131 • Number of events 1 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	0.88% 1/113 • Number of events 1 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	0.82% 2/244 • Number of events 2 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.
Nervous system disorders LUMBOSACRAL RADICULOPATHY	0.00% 0/131 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	0.88% 1/113 • Number of events 1 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	0.41% 1/244 • Number of events 1 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.
Nervous system disorders ON AND OFF PHENOMENON	0.76% 1/131 • Number of events 2 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	0.00% 0/113 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	0.41% 1/244 • Number of events 2 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.
Nervous system disorders PARAESTHESIA	0.00% 0/131 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	0.88% 1/113 • Number of events 1 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	0.41% 1/244 • Number of events 1 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.
Nervous system disorders PARKINSON'S DISEASE	3.8% 5/131 • Number of events 6 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	0.88% 1/113 • Number of events 1 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	2.5% 6/244 • Number of events 7 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.
Nervous system disorders PARKINSONISM	0.00% 0/131 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	0.88% 1/113 • Number of events 1 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	0.41% 1/244 • Number of events 1 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.
Nervous system disorders PSYCHOGENIC SEIZURE	0.00% 0/131 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	0.88% 1/113 • Number of events 1 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	0.41% 1/244 • Number of events 1 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.
Psychiatric disorders ANXIETY	0.00% 0/131 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	0.88% 1/113 • Number of events 1 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	0.41% 1/244 • Number of events 1 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.
Psychiatric disorders CONFUSIONAL STATE	0.00% 0/131 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	0.88% 1/113 • Number of events 1 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	0.41% 1/244 • Number of events 1 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.
Psychiatric disorders DELIRIUM	0.76% 1/131 • Number of events 1 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	0.88% 1/113 • Number of events 1 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	0.82% 2/244 • Number of events 2 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.
Psychiatric disorders DELUSION	0.76% 1/131 • Number of events 1 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	0.88% 1/113 • Number of events 1 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	0.82% 2/244 • Number of events 2 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.
Psychiatric disorders DELUSIONAL DISORDER, UNSPECIFIED TYPE	0.00% 0/131 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	0.88% 1/113 • Number of events 1 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	0.41% 1/244 • Number of events 1 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.
Psychiatric disorders DOPAMINE DYSREGULATION SYNDROME	0.76% 1/131 • Number of events 1 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	0.00% 0/113 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	0.41% 1/244 • Number of events 1 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.
Psychiatric disorders HALLUCINATION	4.6% 6/131 • Number of events 6 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	0.88% 1/113 • Number of events 1 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	2.9% 7/244 • Number of events 7 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.
Psychiatric disorders PSYCHOTIC DISORDER	3.1% 4/131 • Number of events 5 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	1.8% 2/113 • Number of events 2 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	2.5% 6/244 • Number of events 7 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.
Psychiatric disorders SUICIDE ATTEMPT	0.76% 1/131 • Number of events 1 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	0.00% 0/113 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	0.41% 1/244 • Number of events 1 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.
Respiratory, thoracic and mediastinal disorders BRONCHIECTASIS	0.76% 1/131 • Number of events 1 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	0.00% 0/113 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	0.41% 1/244 • Number of events 1 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.
Respiratory, thoracic and mediastinal disorders DYSPNOEA	0.00% 0/131 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	0.88% 1/113 • Number of events 1 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	0.41% 1/244 • Number of events 1 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.
Respiratory, thoracic and mediastinal disorders HYPERVENTILATION	0.00% 0/131 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	0.88% 1/113 • Number of events 1 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	0.41% 1/244 • Number of events 1 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.
Respiratory, thoracic and mediastinal disorders PULMONARY EMBOLISM	0.00% 0/131 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	0.88% 1/113 • Number of events 1 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	0.41% 1/244 • Number of events 1 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.
Vascular disorders HAEMATOMA	0.00% 0/131 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	0.88% 1/113 • Number of events 1 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	0.41% 1/244 • Number of events 1 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.
Vascular disorders HAEMORRHAGE	0.00% 0/131 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	0.88% 1/113 • Number of events 1 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	0.41% 1/244 • Number of events 1 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.
Vascular disorders ORTHOSTATIC HYPOTENSION	0.76% 1/131 • Number of events 1 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	0.00% 0/113 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	0.41% 1/244 • Number of events 1 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.

Other adverse events

Measure	ABBV-951 Low Dose Subgroup n=131 participants at risk After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was \< 2530 mg of Foslevodopa/day were analyzed as the Low Dose Subgroup.	ABBV-951 High Dose Subgroup n=113 participants at risk After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was ≥ 2530 mg of Foslevodopa/day were analyzed as the High Dose Subgroup.	ABBV-951 All Participants n=244 participants at risk After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period.
Gastrointestinal disorders CONSTIPATION	6.1% 8/131 • Number of events 8 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	10.6% 12/113 • Number of events 12 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	8.2% 20/244 • Number of events 20 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.
Gastrointestinal disorders NAUSEA	6.1% 8/131 • Number of events 11 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	9.7% 11/113 • Number of events 13 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	7.8% 19/244 • Number of events 24 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.
General disorders INFUSION SITE BRUISING	7.6% 10/131 • Number of events 15 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	7.1% 8/113 • Number of events 15 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	7.4% 18/244 • Number of events 30 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.
General disorders INFUSION SITE ERYTHEMA	48.9% 64/131 • Number of events 175 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	55.8% 63/113 • Number of events 168 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	52.0% 127/244 • Number of events 343 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.
General disorders INFUSION SITE EXTRAVASATION	6.1% 8/131 • Number of events 10 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	10.6% 12/113 • Number of events 15 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	8.2% 20/244 • Number of events 25 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.
General disorders INFUSION SITE HAEMATOMA	7.6% 10/131 • Number of events 10 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	6.2% 7/113 • Number of events 12 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	7.0% 17/244 • Number of events 22 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.
General disorders INFUSION SITE INFLAMMATION	2.3% 3/131 • Number of events 3 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	5.3% 6/113 • Number of events 9 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	3.7% 9/244 • Number of events 12 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.
General disorders INFUSION SITE NODULE	27.5% 36/131 • Number of events 65 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	30.1% 34/113 • Number of events 58 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	28.7% 70/244 • Number of events 123 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.
General disorders INFUSION SITE OEDEMA	14.5% 19/131 • Number of events 78 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	24.8% 28/113 • Number of events 45 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	19.3% 47/244 • Number of events 123 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.
General disorders INFUSION SITE PAIN	13.7% 18/131 • Number of events 41 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	17.7% 20/113 • Number of events 27 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	15.6% 38/244 • Number of events 68 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.
General disorders INFUSION SITE PAPULE	5.3% 7/131 • Number of events 8 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	9.7% 11/113 • Number of events 18 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	7.4% 18/244 • Number of events 26 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.
General disorders INFUSION SITE REACTION	9.9% 13/131 • Number of events 26 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	15.0% 17/113 • Number of events 36 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	12.3% 30/244 • Number of events 62 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.
General disorders INJECTION SITE ERYTHEMA	4.6% 6/131 • Number of events 22 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	7.1% 8/113 • Number of events 14 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	5.7% 14/244 • Number of events 36 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.
General disorders INJECTION SITE NODULE	2.3% 3/131 • Number of events 15 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	5.3% 6/113 • Number of events 8 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	3.7% 9/244 • Number of events 23 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.
General disorders INJECTION SITE PAIN	1.5% 2/131 • Number of events 2 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	5.3% 6/113 • Number of events 6 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	3.3% 8/244 • Number of events 8 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.
Infections and infestations INFUSION SITE ABSCESS	6.9% 9/131 • Number of events 9 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	8.8% 10/113 • Number of events 12 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	7.8% 19/244 • Number of events 21 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.
Infections and infestations INFUSION SITE CELLULITIS	19.1% 25/131 • Number of events 33 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	18.6% 21/113 • Number of events 31 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	18.9% 46/244 • Number of events 64 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.
Infections and infestations INFUSION SITE INFECTION	5.3% 7/131 • Number of events 8 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	8.8% 10/113 • Number of events 16 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	7.0% 17/244 • Number of events 24 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.
Infections and infestations URINARY TRACT INFECTION	4.6% 6/131 • Number of events 7 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	8.0% 9/113 • Number of events 14 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	6.1% 15/244 • Number of events 21 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.
Injury, poisoning and procedural complications CONTUSION	1.5% 2/131 • Number of events 3 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	5.3% 6/113 • Number of events 9 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	3.3% 8/244 • Number of events 12 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.
Injury, poisoning and procedural complications FALL	12.2% 16/131 • Number of events 42 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	20.4% 23/113 • Number of events 35 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	16.0% 39/244 • Number of events 77 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.
Injury, poisoning and procedural complications SKIN LACERATION	0.76% 1/131 • Number of events 1 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	5.3% 6/113 • Number of events 6 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	2.9% 7/244 • Number of events 7 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.
Investigations VITAMIN B6 DECREASED	3.8% 5/131 • Number of events 5 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	5.3% 6/113 • Number of events 6 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	4.5% 11/244 • Number of events 11 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.
Investigations WEIGHT DECREASED	7.6% 10/131 • Number of events 10 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	12.4% 14/113 • Number of events 14 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	9.8% 24/244 • Number of events 24 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.
Musculoskeletal and connective tissue disorders BACK PAIN	6.1% 8/131 • Number of events 8 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	4.4% 5/113 • Number of events 6 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	5.3% 13/244 • Number of events 14 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.
Nervous system disorders DIZZINESS	10.7% 14/131 • Number of events 18 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	8.8% 10/113 • Number of events 10 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	9.8% 24/244 • Number of events 28 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.
Nervous system disorders DYSKINESIA	9.2% 12/131 • Number of events 20 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	5.3% 6/113 • Number of events 7 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	7.4% 18/244 • Number of events 27 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.
Nervous system disorders HEADACHE	5.3% 7/131 • Number of events 7 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	6.2% 7/113 • Number of events 10 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	5.7% 14/244 • Number of events 17 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.
Nervous system disorders PARKINSON'S DISEASE	5.3% 7/131 • Number of events 8 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	3.5% 4/113 • Number of events 4 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	4.5% 11/244 • Number of events 12 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.
Nervous system disorders SOMNOLENCE	6.9% 9/131 • Number of events 11 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	2.7% 3/113 • Number of events 3 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	4.9% 12/244 • Number of events 14 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.
Psychiatric disorders ANXIETY	7.6% 10/131 • Number of events 12 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	15.9% 18/113 • Number of events 22 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	11.5% 28/244 • Number of events 34 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.
Psychiatric disorders DELUSION	5.3% 7/131 • Number of events 8 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	0.88% 1/113 • Number of events 1 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	3.3% 8/244 • Number of events 9 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.
Psychiatric disorders HALLUCINATION	10.7% 14/131 • Number of events 22 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	18.6% 21/113 • Number of events 27 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	14.3% 35/244 • Number of events 49 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.
Psychiatric disorders HALLUCINATION, VISUAL	7.6% 10/131 • Number of events 14 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	4.4% 5/113 • Number of events 6 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	6.1% 15/244 • Number of events 20 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.
Psychiatric disorders INSOMNIA	6.9% 9/131 • Number of events 9 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	8.0% 9/113 • Number of events 9 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	7.4% 18/244 • Number of events 18 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.
Vascular disorders ORTHOSTATIC HYPOTENSION	4.6% 6/131 • Number of events 6 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	5.3% 6/113 • Number of events 7 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.	4.9% 12/244 • Number of events 13 • All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.

Additional Information

Global Medical Services

AbbVie

Phone: 800-633-9110

Email: abbvieclinicaltrials@abbvie.com

Results disclosure agreements

• Principal investigator is a sponsor employee AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.
• Publication restrictions are in place

Restriction type: OTHER